NATIONAL GUIDELINES ON PREVENTION, MANAGEMENT AND CONTROL OF REPRODUCTIVE TRACT INFECTIONS INCLUDING SEXUALLY TRANSMITTED INFECTIONS
National Guidelines on Prevention, Management and Control of Reproductive Tract Infections including Sexually Transmitted Infections

Coordinated by

National Institute for Research in Reproductive Health
Indian Council of Medical Research

Supported by

Ministry of Health and Family Welfare
Government of India
## Contents

<table>
<thead>
<tr>
<th>S.No.</th>
<th>Topic</th>
<th>Page Nos.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Preface</td>
<td>vi</td>
</tr>
<tr>
<td></td>
<td>Acknowledgement</td>
<td>viii</td>
</tr>
<tr>
<td></td>
<td>List of Abbreviations</td>
<td>x</td>
</tr>
<tr>
<td></td>
<td>List of Figures</td>
<td>xii</td>
</tr>
<tr>
<td>1.</td>
<td>Introduction</td>
<td>1</td>
</tr>
<tr>
<td>2.</td>
<td>Clinical Spectrum of RTIs/STIs</td>
<td>4</td>
</tr>
<tr>
<td>3.</td>
<td>Objectives of RTI/STI Case Management Services</td>
<td>8</td>
</tr>
<tr>
<td>4.</td>
<td>Case Management</td>
<td>9</td>
</tr>
<tr>
<td>5.</td>
<td>Diagnosis and Management of RTIs/STIs</td>
<td>22</td>
</tr>
<tr>
<td>6.</td>
<td>RTIs/STIs among Special Populations</td>
<td>47</td>
</tr>
<tr>
<td>7.</td>
<td>Management of Sexual Violence</td>
<td>53</td>
</tr>
<tr>
<td>8.</td>
<td>Counselling Testing for RTIs/STIs</td>
<td>56</td>
</tr>
<tr>
<td>9.</td>
<td>Annexures</td>
<td></td>
</tr>
<tr>
<td>1.</td>
<td>Laboratory tests for RTIs/STIs</td>
<td>58</td>
</tr>
<tr>
<td>2.</td>
<td>Condoms and their proper usage technique</td>
<td>68</td>
</tr>
<tr>
<td>3.</td>
<td>STI Clinic Setup</td>
<td>71</td>
</tr>
<tr>
<td>4.</td>
<td>List of Drugs</td>
<td>73</td>
</tr>
<tr>
<td>5.</td>
<td>Disinfection and Universal Precaution</td>
<td>74</td>
</tr>
<tr>
<td>6.</td>
<td>Monthly monitoring format</td>
<td>81</td>
</tr>
<tr>
<td>7.</td>
<td>References and Source</td>
<td>85</td>
</tr>
<tr>
<td>8.</td>
<td>List of Contributors</td>
<td>87</td>
</tr>
</tbody>
</table>
Preface

Reproductive tract infections (RTIs) including sexually transmitted infections (STIs) present a huge burden of disease and adversely impacts the reproductive health of people. They cause suffering for both men and women around the world, but their consequences are far more devastating and widespread among women than among men. The exact data on STI prevalence in India especially in the general population is lacking. The disease prevalence is estimated to be 6% in India and a total of 30 million people may be affected out of 340 million world over. The estimates also indicate that about 40% of women have RTI/STI at any given point of time but only 1% completes the full treatment of both partners. The emergence of HIV and identification of STIs as a cofactor have further lent a sense of urgency for formulating a programmatic response to address this important public health problem.

It has been prominently agreed in the 10th Plan document of the Government of India and the need has been reflected in the National Population Policy (2000) “to include STD/RTI and HIV/AIDS prevention, screening and management in maternal and child health services”. In the Phase-I of the National Reproductive and Child Health (RCH) program in India, STI/RTI services could not be operationalised below the district level and remain fragmented under National AIDS Control Programme (NACP). Therefore, management of RTIs is the most needed inclusion, particularly in the rural and urban slum areas of our country in Phase 2 of the RCH Programme and Phase 3 of NACP.

The National Rural Health Mission (NRHM), launched in April, 2005, aims to provide accessible, affordable, effective, accountable and reliable health care consistent with the general principles laid down in the National and State policies. Under the umbrella of NRHM, the RCH 2 envisages operationalization of First Referral Units, Community Health Centres and at least 50% of 24x7 Primary Health Centres. All these facilities shall provide a range of maternal health services including skilled care at birth, essential and emergency obstetric care, safe abortion and RTI/STI prevention and management services. On the operational side, Indian Public Health Standards (IPHS) are being prescribed to achieve and maintain quality care to the community. The current guidelines under NRHM converge the needs of the two programs and bring uniformity in protocols for RTI/STI management across the country.

These guidelines are intended as a resource document for the programme managers and service providers in RCH 2 and NACP 3 and would enable the RCH service providers in organizing effective case management services through the public health system especially through the network of 24 hour PHCs and CHCs. It would also facilitate up-scaling of targeted interventions (TIs) for sex workers by programme managers and provision of quality STI management services. The guidelines have been developed keeping in mind the variability in the two programme settings and is a very good example
of convergence between the RCH and NACP. It will also succeed in bringing in a focus on HIV/AIDS with uniform protocols for treatment and management of RTIs/STIs.

The Division of Maternal Health and National AIDS Control Organisation, Ministry of Health & Family Welfare in collaboration with National Institute for Research in Reproductive Health (NIRRH), Indian Council of Medical Research have prepared the technical guidelines which will help Medical Officers, and Programme Managers to mainstream RTI/STI prevention, management, and control in the health care delivery system. I congratulate the concerned departments, NIRRH, ICMR, WHO Country Office, UNFPA, and experts who have given their valuable assistance for the development of these guidelines. I am sure that these guidelines, when implemented in word and spirit, will go a long way in correctly positioning RTI/STI management in our country.

(Naresh Dayal)
Secretary
Ministry of Health & Family Welfare
Government of India
Reproductive tract infections including sexually transmitted infections (RTIs/STIs) are recognized as a public health problem, particularly due to their relationship with HIV infection. The prevention, control and management of RTIs/STIs is a well recognized strategy for controlling the spread of HIV/AIDS in the country as well as to reduce reproductive morbidity among sexually active population.

The convergence framework of National Rural Health Mission (NRHM) provided the directions for synergizing the strategies for prevention, control and management for RTI/STI services under Phase 2 of Reproductive and Child Health Programme (RCH 2) and Phase 3 of National AIDS Control Programme (NACP 3). While the RCH draws its mandate from the National Population Policy (2000) which makes a strong reference “to include STI/RTI and HIV/AIDS prevention, screening and management in maternal and child health services”, the NACP includes services for management of STIs as a major programme strategy for prevention of HIV. The NACP Strategy and Implementation Plan (2006-2011) makes a strong reference to expanding access to a package of STI management services both in general population groups and for high risk behavior groups and also acknowledges that expanding access to services will entail engaging private sector in provision of services.

The highlights of the document include comprehensive RTI/STI case management approach including detailed history taking and clinical examination; user friendly management flowcharts including syndrome-specific partner management and management of pregnant women; effective drug regimens, single oral dosages wherever possible; issues of privacy and confidentiality, and partner management is given special focus. The guidelines also emphasize on counseling for safe sex, condom promotion, dual protection options and integration of RTIs/STIs assessment into Family Planning services. Special population segments like neonates, adolescents and high risk groups are addressed separately.

The vision and constant encouragement provided by Shri Prasanna Hota, former Secretary, Ministry of Health and Family Welfare enabled us to bring out these guidelines. We also express our sincere thanks to Shri Naresh Dayal, Secretary, Health and Family Welfare under whose leadership these guidelines have been finalized.

A number of organizations, individuals and professional bodies have contributed towards the development of these guidelines. National Institute of Research in Reproductive Health (NIRRH), Mumbai under ICMR led the process of country wide rapid assessment survey and coordinated the development of technical guidelines. We express our sincere appreciation to Dr Chander Puri, Director and Dr Sanjay Chauhan, Deputy Director of NIRRH who provided the support in the development of these
Guidelines for Setting Up Blood Storage Centres

We would also like to thank the members of the operational, clinical and laboratory working and advisory groups constituted at the NIRRH and NACO for providing their expertise, experience and guidance in outlining the guidelines.

These guidelines have been prepared and designed with technical assistance and other related support provided by WHO, UNFPA, FHI and other experts in the field. Special thanks are due to Dr Arvind Mathur, Coordinator, Family & Community Health, WHO, -India for providing continued support and contributing technically to bring the guidelines to the current shape. We are particularly thankful to Dr Dinesh Agarwal, Technical Advisor, Reproductive Health, UNFPA India office, Dr H. K. Kar, Professor and Head, Department of Dermatology & STD, RML Hospital, Dr. N. Usman, Professor of Dermatology and STD, Chennai for their constant technical inputs, unstinted support and guidance through out the process of developing these guidelines.

We would like to express our sincere appreciation for the encouragement and guidance provided by Shri S. S. Brar, Joint Secretary (RCH), Dr. I. P. Kaur, Deputy Commissioner, Maternal Health and Dr. Jotna Sokhey, Additional Project Director, NACO. We also appreciate guidance provided by Dr. V. K. Manchanda, the erstwhile Deputy Commissioner, Maternal and Child Health during the preparation of this document. The hard work and contributions of Dr. Ajay Khera, Joint Director, NACO, Dr. Himanshu Bhushan and Dr. Manisha Malhotra, Assistant Commissioners, Maternal Health Division have been invaluable in shaping the document. We also appreciate the excellent contributions of Dr. Vinod Khurana, Consultant, NACO in finalizing the guidelines.

S. Jalaja
Additional Secretary
Mission Director
National Rural Health Mission

Sujatha Rao
Additional Secretary
Project Director
National AIDS Control Organisation

Ministry of Health and Family Welfare
Government of India
New Delhi
# List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>AIDS</td>
<td>Acquired Immunodeficiency Syndrome</td>
</tr>
<tr>
<td>ANC</td>
<td>Anti Natal Care</td>
</tr>
<tr>
<td>ART</td>
<td>Anti Retroviral Therapy</td>
</tr>
<tr>
<td>ANMs</td>
<td>Auxillary Nurse Midwives</td>
</tr>
<tr>
<td>BV</td>
<td>Bacterial Vaginosis</td>
</tr>
<tr>
<td>CA</td>
<td>Candidiasis, yeast infection</td>
</tr>
<tr>
<td>CHCs</td>
<td>Community Health Centres</td>
</tr>
<tr>
<td>CMV</td>
<td>Cyto MegaloVirus</td>
</tr>
<tr>
<td>CDC</td>
<td>Centre for Disease Control</td>
</tr>
<tr>
<td>EC</td>
<td>Emergency Contraception</td>
</tr>
<tr>
<td>ESR</td>
<td>Erythrocyte Sedimentation Rate</td>
</tr>
<tr>
<td>ELISA</td>
<td>Enzyme Linked Immuno Sorbent Assay</td>
</tr>
<tr>
<td>Endo</td>
<td>Endogenous</td>
</tr>
<tr>
<td>FPFHI</td>
<td>Family PlanningFamily Health International</td>
</tr>
<tr>
<td>FTA-Abs</td>
<td>Fluorescent Treponema Antibody Absorption Test</td>
</tr>
<tr>
<td>GUD</td>
<td>Genital Ulcer Disease</td>
</tr>
<tr>
<td>HBV</td>
<td>Hepatitis B Virus</td>
</tr>
<tr>
<td>HIV</td>
<td>Human Immunodeficiency Virus</td>
</tr>
<tr>
<td>HPV</td>
<td>Human Papilloma Virus</td>
</tr>
<tr>
<td>HSV</td>
<td>Herpes Simplex Virus</td>
</tr>
<tr>
<td>Iatro</td>
<td>Iatrogenic</td>
</tr>
<tr>
<td>IPHS</td>
<td>Indian Public Health Standards</td>
</tr>
<tr>
<td>ICTC</td>
<td>Integrated Counselling and Testing Centre</td>
</tr>
<tr>
<td>IDUs</td>
<td>Intravenous Drug Users</td>
</tr>
<tr>
<td>IM</td>
<td>Intramuscular</td>
</tr>
<tr>
<td>IU</td>
<td>International Units</td>
</tr>
<tr>
<td>IUD</td>
<td>Intra Uterine Device</td>
</tr>
<tr>
<td>IV</td>
<td>Intravenous</td>
</tr>
<tr>
<td>KOH</td>
<td>Potassium Hydroxide</td>
</tr>
<tr>
<td>LGV</td>
<td>LymphoGranuloma Venereum</td>
</tr>
<tr>
<td>LHV</td>
<td>Lady Health Visitor</td>
</tr>
<tr>
<td>MOHFW</td>
<td>Ministry of Health and Family Welfare</td>
</tr>
</tbody>
</table>
List of Figures

Fig 4a: Lesions of secondary syphilis
Fig 4b: Mucous patches in secondary syphilis
Fig 4c: Vesicles of Genital Herpes
Fig 4d: Abrasions of Intertrigo
Fig 4e: Extensive mucopurulent cervicitis infection
Fig 4f: Pus pouring out of endocervix in Chlamydia infection
Fig 4g: Growth of genital warts
Fig 4h: Chancre of Syphilis
Fig 4i: Urethral discharge in gonorrhea
Fig 4j: Herpes ulcers
Fig 4k: Multiple grouped erosions over shaft of penis
Fig 4l: Chancre of glans in Syphilis
Fig 4m: Chancre of coronal sulcus in Syphilis
Fig 4n: Ulcer of Donovanosis
Fig 4o: Condyloma lata of Syphilis
Fig 4p: Veneral warts
Fig 4q: Candidial balanoposthitis
Fig 4r: Chancroidal bubo: note the single pointing
Fig 4s: LGV
Fig 5a: Perivulval warts
Fig 5b: Penile warts
Fig 5c: Perianal warts
Fig 5d: Molluscum contagiosum
Fig 5e: Genital Scabies
Fig A1a: Collection of specimen on swab
Fig A1b: Potassium hydroxide preparation of vaginal fluid showing budding yeast and mycelia
Fig A1c: “Clue cells” in vaginal wet mount (x 400)
Fig A1d: *Trichomonas vaginalis* in a wet mount of vaginal discharge (x 400)
Fig A1e: Gram stained vaginal smear showing a normal flora of lactobacilli (x 1000)
Fig A1f: Gram stained vaginal smear with typical “clue cell” (x 1000)
Fig A1g: Gram stained vaginal smear showing large Gram-negative rods (Mobilincus mulieris) (x 1000)
Fig A1h: Gram stain smear - Gram-negative diplococci of *Neisseria gonorrhoeae*
Fig A1i: Test serum is mixed with antigen and the card is placed on appropriate rotator
Fig A1j: Reading RPR results for 10 undiluted sera showing reactive and non reactive samples.
Fig: A5a: Hand washing Procedures

**LIST OF TABLES**

Table 2.1: Causative organisms and presenting symptoms & signs of specific RTIs/STIs
Table A5a: Management of health care waste
Table A5b: Hypochlorite solution of 0.5 % 1% and 2 % available chlorine
Table A5c: Common disinfectants used for environmental cleaning in health center

**LIST OF BOXES**

Box 4.1: Sample questions on history taking
Box 4.2: Signs to look for during external genital examination of a female
Box 4.3: Speculum examination in women
Box 4.4: Signs to look for during speculum examination
Box 4.5: Bimanual pelvic examination
Box 4.6: Signs to look for during a bimanual examination
Box 4.7: Signs to look for when examining men
Box 5.1: Important considerations for management of all clients of RTIs/STIs
Box 5.2: Coupon for free examination
Box 5.3: Management of treatment failure and re-infection
Box 7.1: Post exposure prophylaxis with Emergency contraceptives
Box 7.2: STI presumptive treatment options for adults and older children and adolescents weighing more than 45 kg
Box 7.3: STI Presumptive treatment options for children
Box A1.1: Wet mount microscopy examination of vaginal discharge
Box A1.2: Clinical criteria for Bacterial vaginosis
Box A1.3: Gram stain microscopy of vaginal smears
Box A1.4: Nugent score
Box A1.5: Procedure of RPR test
Box A1.6: Interpreting serological test results
Box A2.1: How to use a male condom
Box A2.2: How to use a Female condom

LIST OF FLOWCHARTS
Flowchart 5.1: Management of Urethral Discharge/Burning Micturition in Males
Flowchart 5.2: Management of Scrotal Swelling
Flowchart 5.3: Management of Inguinal Bubo
Flowchart 5.4: Management of Genital Ulcers
Flowchart 5.5: Management of Vaginal Discharge in Females
Flowchart 5.6: Management of Lower Abdominal Pain in Females
Flowchart 5.7: Management of Oral & Anal STIs
Flowchart 6.1: Management of STIs during routine visit by female sex workers
Flowchart 6.2: Flowchart for routine visit by male and transgender sex workers in clinics
1 Introduction

Sexually transmitted infections (STIs) present a huge burden of disease and adversely impact reproductive health of people. As per recent STI prevalence study (2003), over 6 percent of adult population in the country suffers from STIs and most regions of country show relatively high levels. It is well known that risk of acquiring HIV infection increases manifold in people with current or prior STI. STIs are linked to HIV transmission as common sexual behaviour put persons at the risk of infection which directly increases the chances of acquiring and transmitting HIV. The emergence of HIV and identification of STIs as a co-factor have further lent a sense of urgency for formulating a programmatic response to address this important public health problem. HIV prevalence rates among STIs Clients also remains high: 22.8 percent in Andhra Pradesh, 15.2 percent in Maharashtra, 12.2 percent in Manipur and 7.4 percent in Delhi.

Besides HIV infections, RTIs including STIs cause suffering for both men and women around the world, but their consequences are far more devastating and widespread among women than among men. These infections often go undiagnosed and untreated, and when left untreated, they lead to complications such as infertility; ectopic pregnancy and cervical cancer. Pelvic inflammatory disease arising from STIs poses a major public health problem and adversely affects the reproductive health of poor and untreated women. Presence of STIs also compromises with contraceptive acceptance and continuation. Similarly some of the RTIs are associated with poor pregnancy outcome and high morbidities and mortalities in neonates and infants.

In developing countries, both the incidence and prevalence of RTIs/STIs are very high, they rank second as the cause of healthy life lost among women of reproductive age group, after maternal morbidity and mortality. In men, sexually transmitted infections combined with HIV infection account for nearly 15 percent of all healthy life lost in the same age group. These infections pose a significant potential drain on public health system resources and contribute substantially to the patterns of major health care expenditure at the household level.

Programmatic response to address prevention, management and control of RTIs/STIs largely falls under the National Reproductive and Child Health (RCH 2) Programme, which was launched in year 2005. The programme draws its mandate from the National Population Policy (2000), which makes a strong reference “to include STD/RTI and HIV/AIDS prevention, screening and management in maternal and child health services” National Rural Health Mission (NRHM) was launched in April, 2005 with an aim to provide accessible, affordable, effective, accountable and reliable health care consistent with the outcomes envisioned in the Millennium Development Goals and general principles laid down in the
National and State policies, including the National Population Policy, 2000 and the National Health Policy, 2002. On the operational side, Indian Public Health Standards (IPHS) are being prescribed to achieve and maintain quality of care to the community through public health care delivery system. Clearly there is renewed emphasis on making public health systems effective to deliver quality services to achieve programme goals.

The National AIDS Control Programme 3 (NACP 3) includes services for management of STIs as a major programme strategy for prevention of HIV. The Strategy and Implementation Plan (2006-2011) makes a strong reference to expanding access to package of STI management services both in general population groups and for high risk behavior groups. Programme also acknowledges that expanding access to services will entail engaging private sector in provision of services. Several studies indicate preference of Clients to access services from private providers. It is also important that treatment facilities in both public and private sector are linked to targeted interventions being supported for high risk behavior groups in the NACP 3.

This document is guided by the National Programme Implementation Plan for RCH 2 and NACP 3. The RCH 2 programme is to be implemented within the framework of inter-sectoral convergence as envisaged in the implementation framework of NRHM. Linkages are to be established between the RCH 2 strategy for prevention and management of RTIs including STIs and prevention strategy as articulated in NACP 3. The inputs required for framing these guidelines are drawn from many sources which also include a multi centric nationwide Rapid Assessment Survey in six zones of the country to assess their management practices (operational, clinical, laboratory) on RTI/STIs at different levels (District, CHC, PHC and Subcentre) of the health system, review of available guidelines, technical discussions with STI care practitioners, and programme managers in public systems as well as from NGO and private sector.

The guidelines presented in this document are designed for qualified Doctors to enable them to quickly and confidently diagnose and treat the majority of the RTIs/STIs caseload. Some part of these guidelines could be extracted and adopted for nursing personnel as per requirements for service delivery in different settings. The main purpose of this document is to present comprehensive RTI/STI case management guidelines including detailed history taking and clinical examination supported by a number of photographs of RTIs/STIs in men and women to provide a visual impression; user friendly management flowcharts including partner management and management of pregnant women; effective drug regimens, single oral dosages wherever possible, with special instructions incorporated in the flowcharts itself. This document also provides guidance to service providers to address RTIs/STIs among special population groups such as adolescents, sex workers and men having sex with men; and simple laboratory tests which can be done at various facility levels with relevant photographs and details of procedures. In addition to this, the document also provides information on organisation of integrated counseling and testing services.

These guidelines cater to information needs of the programme managers and
service providers in RCH 2 and also in NACP 3. The RCH service providers will find the information useful in organizing effective case management services through public health system especially through network of 24 hour PHCs and CHCs. Similarly programme managers specially State AIDS Control Society officers entrusted with the responsibility of up scaling targeted interventions (TIs) for sex workers and TI managers will find useful information for provision of quality STI management services.

Recognizing the fact that a significantly high proportion of these clients are being treated through private sectors, the private providers/ NGO service providers are highly encouraged to use these national protocols.
Clients suspected of having RTIs/STIs usually present with one or more of the following complaints:

(i) Vaginal or urethral discharge;
(ii) Vesicular and/or non-vesicular genital ulcers;
(iii) Inguinal bubo;
(iv) Lower abdominal and/or scrotal pain; and
(v) Genital skin conditions.

The following table depicts presenting symptoms, signs, clinical conditions, and causative organisms.

### Table 2. Causative organisms and presenting symptoms & signs of specific RTIs STIs

<table>
<thead>
<tr>
<th>RTI STI</th>
<th>Causative Organism</th>
<th>Symptoms/Signs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presenting symptoms: Vaginal/Urethral Discharge and or burning micturition</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gonorrhea</td>
<td>Neisseria gonorrhoe</td>
<td>Women</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Purulent (containing mucopus) vaginal discharge</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Pain or burning on passing urine (dysuria)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Inflamed (red and tender) urethral opening</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Men</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Pain or burning on passing urine (dysuria)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Purulent (containing mucopus) urethral discharge (drip).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Infection of the epididymis (coiled tube leading from the testis to the vas deferens)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Urethral abscess or narrowing (stricture)</td>
</tr>
<tr>
<td>Trichomoniasis</td>
<td>Trichomonas vaginalis</td>
<td>• May produce few symptoms in either sex</td>
</tr>
</tbody>
</table>
### Guidelines for Setting Up Blood Storage Centres

- Women often will have a frothy (bubbly), foul-smelling, greenish vaginal discharge.
- Men may have a urethral discharge.

<table>
<thead>
<tr>
<th>Chlamydia</th>
<th>Chlamydia trachomatis</th>
<th><strong>Women</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>• Produces few symptoms, even with upper genital tract infection (silent PID)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Purulent cervical discharge, frequently a “beefy” red cervix which is friable (bleeds easily)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Men</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Most frequent cause of non-gonococcal urethritis (NGU)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Bacterial vaginosis</th>
<th>Overgrowth of anaerobes (e.g., Gardnerella vaginalis)</th>
<th><strong>Women</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>• Not necessarily sexually transmitted</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Vaginal discharge with fishy odor, grayish in color</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Candidiasis</th>
<th>Candida albicans</th>
<th><strong>Women</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>• Curd-like vaginal discharge, whitish in color</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Moderate to intense vaginal or vulval itching (pruritus)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Men</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Itchy penile irritation (balanitis)</td>
</tr>
</tbody>
</table>

**Presenting symptoms:**

- Chancroid (Soft chancre)
- Haemophilus ducreyi
- Painful, “dirty” ulcers located anywhere on the external genitalia.
- Development of painful enlarged lymph nodes (bubo) in the groin.

- Lymphogranuloma venereum (LGV)
- Chlamydia trachomatis (serovars L1, L2, L3)
- Small, usually painless papules (like pimples) on the penis or vulva, followed by
- Buboes in the groin which ultimately breaks down forming multiple fistulae (draining openings)
- If untreated, the lymphatic system may become blocked, producing elephantiasis (swelling of the genitals or extremities)

- Syphilis
- Treponema Pallidum
- Occurs in 3 stages: primary and secondary and late
**Primary syphilis**
- Initially, painless ulcer (chancre): in women on the external genitalia (labia), in men on the penis; in both sexes oral and anal ulcers and enlarged rubbery lymph nodes

**Secondary (disseminated) syphilis**
- Several months later non-itchy body rash, headaches, muscle aches, weight loss, low grade fever. The rashes may disappear spontaneously

**Late syphilis**
- Develops in about 25% of untreated cases and is often fatal due to involvement of the heart, great blood vessels and brain

<table>
<thead>
<tr>
<th>Granuloma inguinale (Donovanosis)</th>
<th>Calymmatobacterium granulomatis</th>
<th>An uncommon cause of ulcerative genital tract infection</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Typically, the infected person develops lumps under the skin which break down to form “beefy” red, painless ulcers</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Genital herpes</th>
<th>Herpes simplex virus</th>
<th>Multiple painful vesicles later forming shallow ulcers which clear in 2 to 4 weeks (first attack) and may be accompanied by watery vaginal discharge in women</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Recurrent (multiple episodes) more than 50% of the time.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pelvic Inflammatory Disease (PID)</th>
<th>Neisseria gonorrhoea</th>
<th>Lower abdominal pain, fever, vaginal discharge, menstrual irregularities like heavy irregular vaginal bleeding, dysmenorrhoea, dyspareunia (pain during sexual intercourse), dysuria, tenesmus, low backache</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chlamydia trachomatis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Anaerobes</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Temperature 39°C</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vaginal/cervical discharge, congestion or ulcers</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lower abdominal tenderness or guarding</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Uterine/adnexal tenderness, cervical movement tenderness, presence of a pelvic mass</td>
</tr>
<tr>
<td>Presenting symptoms:</td>
<td>c e scro al ain an or s ollen scro m</td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------------------------------</td>
<td></td>
</tr>
</tbody>
</table>
| **Epididymitis/ Orchitis** | • Neisseria gonorrhea  
• Chlamydia trachomatis  
• Acute: severe pain in one or both testes, sudden swelling of the testes. |
| **Presenting symptoms: eni al in on ions** | |
| **Genital warts** (Condyloma acuminata) | Human papilloma virus | • Single or multiple soft, painless, “cauliflower” growth which appear around the anus, vulvo- vaginal area, penis, urethra and perineum |
| **Molluscum contagiosum** | Pox virus | • Multiple, smooth, glistening, globular papules of varying size from a pinhead to a split pea can appear anywhere on the body. Sexually transmitted lesions on or around genitals can be seen.  
• Not painful except when secondary infection sets in. |
| **Pediculosis pubis** | Pthirus pubis | • There may be small red papules with a tiny central clot caused by lice irritation.  
• General or local urticaria with skin thickening may or may not be present. |
| **Scabies** | Sarcoptes scabiei | • Severe pruritis (itching) is experienced by the client which becomes worse at night.  
• The burrow is the diagnostic sign. It can be seen as a slightly elevated grayish dotted line in the skin, best seen in the soft part of the skin. |
3 Objectives of RTI/STI Case Management Services

Provision of quality RTI/STI case management services through a network of public health care delivery institutions, private sector providers, franchisee clinics and in targeted intervention settings will result in achieving following objectives:

1. Enhance access to services to all; especially for women and adolescents who are constrained to seek services and face several access related barriers.

2. Standardized treatment protocols will improve prescription practices by reducing poly pharmacy, irrational drug combinations.

3. Focus on prevention, with special reference to partner management, condom use, follow-ups and management of side effects.

4. Emphasis on treatment compliance and better treatment outcomes.

5. Behaviour change communication leading to improved knowledge on causation, transmission and prevention of RTIs/STIs.

6. Ensure that providers offer counseling and testing services for HIV/AIDS and establish linkages with ART systems with respect to persons detected positives.

7. Screen asymptomatic women especially contraceptive users and antenatal clients for STIs.

8. Ensure service provision for groups practicing high risk behaviors such as sex workers, MSMs and IDUs.
The most important elements of RTI/STI case management are accurate diagnosis and effective treatment. This needs time and skill in taking a detailed sexual history for both client and his/her sexual contacts and in carrying out a comprehensive physical examination and minimal investigations in resource poor settings. In some settings where even minimal laboratory setup and facilities for clinical examinations are not available, syndromic management is recommended as per the protocols in following pages. To prevent the complications and spread, treatment must be effective. This means selecting the correct drugs for the disease, carefully monitoring its administration and carrying out regular follow up. The sexual partners must be treated so as to prevent recurrence. Clients should also receive counseling services with special reference to risk reduction, safer sex behaviour and access to testing.

Thus, quality case management consists not only of antimicrobial therapy to obtain cure and reduce infectivity, but also focus on prevention of recurrence and partner management.

**History taking**

- History must be taken in a language, which the client understands well. (Some examples of framed questions are given in Box 1). Clients are often reluctant to talk about these conditions due to shyness or fear of stigmatization. Hence health care providers should ensure privacy, confidentiality, be sympathetic, understanding, non-judgmental and culturally sensitive.

- Ensure privacy by having a separate room for history taking and examination, which is not stigmatized with a nameplate for STIs. There should be auditory as well as visual privacy for history taking as well as examination.

- Start the conversation by welcoming your client, taking them into confidence and encouraging him/her to talk about their complaints. If a couple comes together, each of them needs to be interviewed and examined separately.

- Often, because the client feels uncomfortable talking about RTIs/STIs, individuals may come to the clinic with other non-specific
complaints or requesting a check-up, assuming that the health care provider will notice anything abnormal that needs treatment. Therefore, health care workers should maintain a high index of suspicion about RTIs/STIs.

- Clients seeking antenatal care and family planning services should be viewed as opportunities to provide general information about RTIs/STIs and should be asked about RTI/STI symptoms and contraception.
- The health care personnel should be aware of the commonly used RTI/STI related terminology as well as those used for high-risk behavior. These terms may vary in different geographical settings.

Clinical examination

Pre requisites for clinical examination
- Clients should be examined in the same conditions of privacy as those in which history was taken.
- It is advisable to have an assistant of the same sex as the client present, during examination of clients of sex opposite to the doctors.
- Clients should be told about the examination with the help of diagrams and charts.
- The examination should be done in a well-lit room while providing adequate comfort and privacy. Before you start, keep the examination table with proper illumination ready as well as sterilized speculums (for examination of female clients), collection swabs and labeled slides for smears.
- As far as possible, complete body examination of the client should be carried out so that none of the skin lesions or lymph nodes is missed.

<table>
<thead>
<tr>
<th>Framing Statement</th>
<th>“In order to provide the best care for you today and to understand your risk for certain infections, it is necessary for us to talk about your sexual behavior.”</th>
</tr>
</thead>
<tbody>
<tr>
<td>Screening questions</td>
<td>Have you recently developed any of these symptoms</td>
</tr>
<tr>
<td>STI (Genital infections) Symptoms Checklist</td>
<td>For Men</td>
</tr>
<tr>
<td>i.</td>
<td>Discharge or pus (drip) from the penis</td>
</tr>
<tr>
<td>ii.</td>
<td>Urinary burning or frequency</td>
</tr>
<tr>
<td>iii.</td>
<td>Genital sores (ulcers) or rash or itching</td>
</tr>
<tr>
<td>iv.</td>
<td>Scrotal swelling</td>
</tr>
</tbody>
</table>
v. Swelling in the groin
vi. Infertility

For Women

i. Abnormal vaginal discharge (increased amount, abnormal odor, abnormal color)
ii. Genital sores (ulcers), rash or Itching
iii. Urinary burning or frequency
iv. Pain in lower abdomen
v. Dysmenorrhoea, menorrhagia, irregular menstrual cycles
vi. Infertility

High risk sexual behavior

- For all adolescents: Have you begun having any kind of sex yet
- If sexually active do you use condom consistently
- Do you have any reason to think you might have a sexually transmitted disease
  If so, what reason
- Have you had sex with any man, woman, with a gay or a bisexual
- Have you or your partner had sex with more than one partner
- Has your sex partner(s) had any genital infections
  If so, which ones
- Do you indulge in high risk sexual activity like anal sex
- Do you practice correct and consistent condom usage while having sex
  If yes, whether every time or sometimes
- Sex workers: Frequency of partner change: use of condoms with regular partners and also with clients

STI History

- In the past have you ever had any genital infections, which could have been sexually transmitted
  If so, can you describe

STI treatment history

- Have you been treated in the past for any genital symptoms
  By whom (qualified or unqualified person)
- Did your partner receive treatment for the same at that time
- Has your partner been treated in the past for any genital symptoms
  By whom (qualified or unqualified person)
Injection Drug Use

- Have you had substance abuse (If yes, have you ever shared needles or injection equipment?)
- Have you ever had sex with anyone who had ever indulged in any form of substance abuse

Menstrual and obstetric history in women and contraceptive history in both sexes should be asked

General Examination

- All examinations should begin with a general assessment, including vital signs and inspection of the skin and mucous patches, to detect signs of systemic disease.

Clinical examination of female clients

While examining a female client, a male doctor should ensure that a female attendant is present. Genital examination in females must be performed with client in lithotomy position.

Fig 4a Lesions of Secondary Syphilis

Fig 4b Mucous patches in Secondary Syphilis
Box 4.2 Signs to look for during external genital examination of a female client

<table>
<thead>
<tr>
<th>a) Inspection</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Staining of underclothes</strong></td>
</tr>
<tr>
<td><strong>Inguinal region</strong></td>
</tr>
<tr>
<td>• Swelling, ulcer, lesions of fungal infections</td>
</tr>
<tr>
<td>• <strong>Lymph nodes</strong></td>
</tr>
<tr>
<td>• Abrasions due to scratching and lesions on inner aspect of thighs</td>
</tr>
<tr>
<td><strong>Pubic area</strong></td>
</tr>
<tr>
<td>• Matting of hairs, pediculosis, folliculitis, or other skin lesions</td>
</tr>
<tr>
<td><strong>Labia majora and minora</strong></td>
</tr>
<tr>
<td>• Separate the labia majora with both hands and look for erythema, edema, esthiomene formation (lobulated fibrosed masses due to chronic lymphedema), fissuring, ulcers, warts or other skin lesions</td>
</tr>
<tr>
<td><strong>Ulcers</strong></td>
</tr>
<tr>
<td>• Location, number (single, multiple), superficial (erosions) or deep, edge (undermined/punched out), margins (regular/irregular) and floor (presence of exudates, slough/granulation tissue)</td>
</tr>
<tr>
<td><strong>Bartholin glands</strong></td>
</tr>
<tr>
<td>• Enlargement, ductal opening, discharge</td>
</tr>
<tr>
<td><strong>Introitus</strong></td>
</tr>
<tr>
<td>• Discharge colour, odour, profuse or scanty, curdy or thin, back drop of redness and inflammation</td>
</tr>
<tr>
<td><strong>Urethral meatus</strong></td>
</tr>
<tr>
<td>• Discharge (pressing under the urethra with one finger may show drops of discharge), inflammation</td>
</tr>
<tr>
<td><strong>Perianal examination</strong></td>
</tr>
<tr>
<td>• Separate the buttocks with two hands for better visualization. Look for ulcer, macerated papules of condyloma lata, warts, discharge, patulous anus, haemorrhoids, fissures, fistula</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>b) Palpation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inguinal region</strong></td>
</tr>
<tr>
<td>• Lymphnodes: tenderness, increased warmth, superficial or deep, discrete or matted, free mobility or fixed to deeper structures, consistency (firm or soft) and fluctuant.</td>
</tr>
<tr>
<td>• Rule out hernia</td>
</tr>
<tr>
<td><strong>Palpation of ulcer at any site</strong></td>
</tr>
<tr>
<td>• Tenderness, induration of the floor and edges, bleeding on maneuvering</td>
</tr>
</tbody>
</table>

Signs of various RTIs/STIs are shown as pictures in fig 4c - 4h. During external genital examination of female clients, one should look for these signs.
Fig 4c Vesicles of Genital Herpes

Fig 4d Abrasions of Intertrigo

Fig 4e Extensive mucopurulent cervicitis infection

Fig 4f Pus pouring out of endocervix in Chlamydia infection

Fig 4g Growth of genital warts

Fig 4h Chancre of Syphilis
Box 4.3: Speculum examination in women

How to do speculum examination in women

- Ask the woman to pass urine.
- Ask her to loosen her clothing. Use a sheet or clothing to cover her.
- Have her lie on her back, with her heels close to her bottom and her knees up.
- Wash your hands well with clean water and soap.
- Put clean gloves on both hands.
- Look at the outside genitals - using the gloved hand to gently look for lumps, swelling, unusual discharge, sores, tears and scars around the genitals and in between the skin folds of the vulva.

Speculum examination

- Be sure the speculum has been properly disinfected before you use it. Wet the speculum with clean water before inserting it.
- Put the first finger of your gloved hand in the woman's vagina. As you put your finger in, push gently downward on the muscle surrounding the vagina (push slowly, waiting for the woman to relax her muscles).
- With the other hand, hold the speculum blades together between the pointing finger and the middle finger. Turn the blades sideways and slip them into the vagina. (be careful not to press on the urethra or clitoris because these area are very sensitive). When the speculum is halfway in, turn it so the handle is down. Remove your gloved finger.
- Gently open the blades a little and look for the cervix. Move the speculum slowly and gently until you can see the cervix between the blades. Tighten the screw on the speculum so it will stay in place.
- Check the cervix which should look pink and round and smooth. Notice if the opening is open or closed, and whether there is any discharge or bleeding. If you are examining the woman because she is bleeding from the vagina after birth, abortion or miscarriage, look for tissue coming from the opening of the cervix.
- Look for signs of cervical infection by checking for yellowish discharge, redness with swelling, or easy bleeding when the cervix is touched with a swab. If the woman has been leaking urine or stools gently turn the speculum to look at the walls of the vagina. Bring the blades closer together to do this.
- To remove the speculum, gently pull it toward you until the blades are clear of the cervix. Then bring the blades together and gently pull back. Be sure to disinfect your speculum again.
Box 4.4: Signs to look for during speculum examination

- Vaginal discharge and redness of the vaginal walls are common signs of vaginitis. Note the color, smell and characteristics of any vaginal discharge. When the discharge is white and curd-like, candidiasis is likely.
- Foreign body, IUD thread.
- Ulcers, warts, sores or blisters.
- Redness of cervical and vaginal epithelium
- Look for cervical erosions. If the cervix bleeds easily when touched or the discharge appears muco-purulent with discoloration, cervical infection is likely. A strawberry appearance of the cervix may be due to trichomoniasis. A uniform bluish discoloration of the cervix may indicate pregnancy, which needs to be kept in mind.
- When examining a woman after childbirth, induced abortion or miscarriage, look for bleeding from the vagina or tissues fragments and check whether the cervix is normal.
- Tumors or other abnormal-looking tissue on the cervix.
- PAP smear can be obtained during speculum examination
Box 4.5: Bimanual pelvic examination

How to do a bimanual pelvic examination

- Put the pointing finger of your gloved hand in the woman’s vagina. As you put your finger in, push gently downward on the muscles surrounding the vagina. When the woman’s body relaxes, put the middle finger in too. Turn the palm of your hand up.

- Feel the opening of her womb (cervix) to see if it is firm (feels like tip of the nose and round. Then put one finger on either side of the cervix and move the cervix gently. It should move easily without causing pain. If it does cause pain, she may have infection of the womb, tubes or ovaries. If her cervix feels soft, she may be pregnant.

- Feel the womb by gently pushing on her lower abdomen with your outside hand. This moves the inside parts (womb, tubes and ovaries) closer to your inside hand. The womb may be tipped forward or backward. If you do not feel it in front of the cervix, gently lift the cervix and feel around it for the body of the womb. If you feel it under the cervix, it is pointed back.

- When you find the womb, feel for its size and shape. Do this by moving your inside fingers to the sides of the cervix, and then walk your outside fingers around the womb. It should feel firm, smooth and smaller than a lemon. If the womb:
  - Feels soft and large, she is probably pregnant.
  - Feels lumpy and hard, she may have a fibroid or other growth.
  - Hurts when you touch it, she may have an infection inside.
  - Does not move freely, she could have scars from an old infection.
  - Feel her tubes and ovaries. If these are normal, they will not be felt. But if you feel any lumps that are bigger than an almond or that cause severe pain, she could have an infection or other emergency. If she has a painful lump, and her monthly bleeding is late, or scanty, she could be pregnant in the tube. She needs medical help right away.

- Move your finger and feel along with inside of the vagina. If she has a problem with leaking urine or stool, check for a tear. Make sure there are no unusual lumps or sores.

- Have the woman cough or push down as if she were passing stool. Watch to see if something bulges out of the vagina. If it does, she could have a fallen womb or fallen bladder (prolapse).

- When you are finished, clean and disinfect your glove. Wash your hands well with soap and water.
### Box 4.6: Signs to look for during a bimanual examination

- Soft enlarged uterus with missed periods suggestive of pregnant uterus
- Adnexal mass with missed periods suggestive of ectopic pregnancy
- Cervical movement tenderness and or adnexal tenderness suggestive of PID
- Adnexal mass with fever suggestive of pelvic abscess
- Any other hard pelvic mass like fibroid or malignancy

#### Digital rectal examination
Performed if symptoms suggestive of prostatic disease. Should not be carried out if the client has painful perianal diseases such as herpetic ulcers, fissures, haemorrhoids.

#### Proctoscopic examination
Indicated if history of unprotected anal intercourse, or complain of rectal discharge.

**Note:** A woman has missed periods should be ruled out by doing a urine pregnancy test.
### Box 4.7: Signs to look for when examining men

<table>
<thead>
<tr>
<th>a) Inspection</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Staining of underclothes</strong></td>
</tr>
<tr>
<td><strong>Inguinal region</strong></td>
</tr>
<tr>
<td><strong>Pubic area</strong></td>
</tr>
<tr>
<td><strong>Scrotum</strong></td>
</tr>
<tr>
<td><strong>Penis</strong></td>
</tr>
<tr>
<td><strong>Inspection of ulcers</strong></td>
</tr>
<tr>
<td><strong>Meatal examination</strong></td>
</tr>
<tr>
<td><strong>Preputial skin examination</strong></td>
</tr>
<tr>
<td><strong>Coronal sulcus</strong></td>
</tr>
<tr>
<td><strong>Glans penis examination</strong></td>
</tr>
<tr>
<td><strong>Shaft of penis</strong></td>
</tr>
<tr>
<td><strong>Perianal examination</strong></td>
</tr>
<tr>
<td>b) Palpation</td>
</tr>
<tr>
<td><strong>Inguinal region</strong></td>
</tr>
<tr>
<td><strong>Palpation of spermatic cords</strong></td>
</tr>
<tr>
<td><strong>Palpation of scrotum</strong></td>
</tr>
</tbody>
</table>
Signs of various RTIs/STIs are shown as pictures in fig . During external genital examination of male clients, one should look for these signs.

Palpation of ulcer at any site  Tenderness, induration of the floor and edges, bleeding on maneuvering.

c) Digital rectal examination  Performed if symptoms suggestive of prostatic disease. Should not be carried out if the client has painful perianal disease such as herpetic ulcers, fissures, or haemorrhoids.

d) Proctoscopic examination  Indicated if unprotected anal intercourse, rectal discharge.
Guidelines for Setting Up Blood Storage Centres

Fig 4l Chancre of glans in syphilis
Fig 4m Chancre of coronal sulcus in syphilis
Fig 4n Ulcer of Donovanosis
Fig 4o Condyloma lata of syphilis
Fig 4p Venereal warts
Fig 4q Candidial balanoposthitis
Fig 4r Chancroidal bubo: note the single pointing
Fig 4s LGV
A simplified tool (flowchart) will help to guide health workers in the management of RTIs/STIs. The flowcharts describe the clinical syndrome, specific RTIs/STIs under the syndrome and the causative organisms of the RTI/STI syndrome. Differential diagnosis of the conditions is also mentioned wherever appropriate. The approach to the client with specific points to be considered during history taking and examination is highlighted. If facilities and skills are available, the laboratory tests which need to be done are also mentioned. The treatment protocols to be followed at the primary health care system with appropriate referrals where indicated is also given. Special emphasis is given on syndrome specific partner management and management issues specific to pregnancy.

**Box 5.1 Important considerations for management of all clients of RTIs/STIs**

- Educate and counsel client and sex partner(s) regarding RTIs/STIs, genital cancers, safer sex practices and importance of taking complete treatment
- Treat partner(s) wherever indicated
- Advise sexual abstinence during the course of treatment
- Provide condoms, educate about correct and consistent use
- Refer for voluntary counseling and testing for HIV, Syphilis and Hepatitis B
- Consider immunization against Hepatitis B
- Schedule return visit after 7 days to ensure treatment compliance as well as to see reports of tests done.
- If symptoms persist, assess whether it is due to treatment failure or re-infection and advise prompt referral.
FLOWCHARTS
Flowchart 5.1: Management of Urethral Discharge/Burning Micturition in Males

- **Causative Organisms**
  - *Neisseria gonorrhoeae*
  - *Chlamydia trachomatis*
  - *Trichomonas vaginalis*

- **RTIs/STIs**: Gonorrhea, Chlamydial Infection, Trichomoniasis

### History of
- Urethral discharge
- Pain or burning while passing urine, increased frequency of urination
- Sexual exposure of either partner to high risk practices including oro-genital sex

### Examination
**Look for**
- The urethral meatus for redness and swelling
- If urethral discharge is not seen, then gently massage the urethra from the ventral part of the penis towards the meatus and look for thick, creamy greenish-yellow or mucoid discharge

### Laboratory Investigations (if available)
- Gram stain examination of the urethral smear will show gram-negative intracellular diplococci in case of gonorrhea.
- In non-gonococcal urethritis more than 5 neutrophils per oil immersion field (1000X) in the urethral smear or more than 10 neutrophils per high power field in the sediment of the first void urine are observed.
Guidelines for Setting Up Blood Storage Centres

Treatment
As dual infection is common, the treatment for urethral discharge should adequately cover therapy for both, gonorrhea and chlamydial infections.

**Recommended regimen for uncomplicated gonorrhea + chlamydia**
Uncomplicated infections indicate that the disease is limited to the anogenital region (anterior urethritis and proctitis).

- **Tab. Cefixime 400 mg orally, single dose**
- **Plus Tab Azithromycin 1 gram orally single dose under supervision**
- **Advise the client to return after 7 days of start of therapy**

When symptoms persist or recur after adequate treatment for gonorrhea and chlamydia in the index client and partner(s), they should be treated for *Trichomonas vaginalis*.

**If discharge or only dysuria persists after 7 days**
- **Tab. Secnidazole 2gm orally, single dose** (to treat for *T. vaginalis*)

**If the symptoms still persist**
- **Refer to higher centre as early as possible**

If individuals are allergic to Azithromycin, give Erythromycin 500 mg four times a day for 7 days.

**Syndrome specific guidelines for partner management**
- Treat all recent partners
- Treat female partners (for gonorrhea and chlamydia) on same lines after ruling out pregnancy and history of allergies
- Advise sexual abstinence during the course of treatment
- Provide condoms, educate about correct and consistent use
- Refer for voluntary counseling and testing for HIV, Syphilis, and Hepatitis B
- Schedule return visit after 7 days

**Management of pregnant partner**
Pregnant partners of male clients with urethral discharge should be examined by doing a per speculum as well as per vaginal examination and should be treated for gonococcal as well as chlamydial infections.

- Cephalosporins to cover gonococcal infection are safe and effective in pregnancy
  - **Tab. Cefixime 400mg orally, single dose**
  - **Ceftriaxone 125mg by intramuscular injection**
  - **Tab. Erythromycin 500mg orally four times a day for seven days**
  - **Cap Amoxicillin 500mg orally, three times a day for seven days to cover chlamydial infection**
  - **Quinolones (like ofloxacin, ciprofloxacin), doxycycline are contraindicated in pregnant women.**

**Follow up**
**After seven days**
- To see reports of tests done for HIV, syphilis and Hepatitis B
- If symptoms persist, to assess whether it is due to treatment failure or re-infection
- For prompt referral if required
Flowchart 5.2: Management of Scrotal Swelling

**Causative Organisms**
- *Neisseria gonorrhoeae*
- *Chlamydia trachomatis*

**History of**
- Swelling and pain in scrotal region
- Pain or burning while passing urine
- Systemic symptoms like malaise, fever
- Sexual exposure of either partner to high risk practices including oro-genital sex

**Examination**

*Look for*
- Scrotal swelling
- Redness and edema of the overlying skin
- Tenderness of the epididymis and vas deferens
- Associated urethral discharge/genital ulcer/inguinal lymph nodes and if present refer to the respective flowchart
- A transillumination test to rule out hydrocoele should be done.

**Laboratory Investigations**
*(If available)*
- Gram stain examination of the urethral smear will show gram-negative intracellular diplococci in case of complicated gonococcal infection
- In non-gonococcal urethritis more than 5 neutrophils per oil immersion field in the urethral smear or more than 10 neutrophils per high power field in the sediment of the first void urine are observed
**Guidelines for Setting Up Blood Storage Centres**

**National AIDS Control Organisation**

### Differential diagnosis (non RTIs STIs)

**Infections causing scrotal swelling**
- Tuberculosis, filariasis, coliforms, pseudomonas, mumps virus infection.

**Non infectious causes**
- Trauma, Hernia, Hydrocoele, Testicular torsion, and Testicular tumors

### Treatment

- **Treat for both gonococcal and chlamydial infections**
  
  **Tab Cefixime 400 mg orally BD for 7 days**
  
  **Cap. Doxycycline 100mg orally, twice daily for 14 days** and refer to higher centre as early as possible since complicated gonococcal infection needs parental and longer duration of treatment

- **Supportive therapy to reduce pain** (bed rest, scrotal elevation with T-bandage and analgesics)

**Note**

If quick and effective therapy is not given, damage and scarring of testicular tissues may result causing sub fertility

### Syndrome specific guidelines for partner management

Partner needs to be treated depending on the clinical findings

### Management protocol in case the partner is pregnant

- Depending on the clinical findings in the pregnant partner (whether vaginal discharge or endocervical discharge or PID is present) the drug regimens should be used.
- Doxycycline is contraindicated in pregnancy
- Erythromycin base/Amoxicillin can be used in pregnancy.
  
  (Erythromycin estolate is contraindicated in pregnancy due to hepatotoxicity. Erythromycin base or erythromycin ethyl succinate should be given)
Flowchart 5.3: Management of Inguinal Bubo

S NDROME ING INAL B BO

RTIs STIs LG , CHANCROID

Causative Organisms
- *Chlamydia trachomatis* serovars L1, L2, L3, causative agent of lympho granuloma venerum (LGV)
- *Haemophilus ducreyi* causative agent of chancroid

History
- Swelling in inguinal region which may be painful
- Preceding history of genital ulcer or discharge
- Sexual exposure of either partner to high risk practices including oro-genital sex
- Systemic symptoms like malaise, fever

Examination
**Look for**
- Localized enlargement of lymph nodes in groin which may be tender and fluctuant
- Inflammation of skin over the swelling
- Presence of multiple sinuses
- Edema of genitals and lower limbs
- Presence of genital ulcer or urethral discharge and if present refer to respective flowchart

Differential diagnosis
- *Mycobacterium tuberculosis*, filariasis
- Any acute infection of skin of pubic area, genitals, buttocks, anus and lower limbs can also cause inguinal swelling
  If malignancy or tuberculosis is suspected refer to higher centre for biopsy.

Laboratory Investigations
Diagnosis is on clinical grounds
**Guidelines for Setting Up Blood Storage Centres**

**Treatment**

- Start Cap. Doxycycline 100mg orally twice daily for 21 days (to cover LGV)
  
  Plus
  
  - Tab Azithromycin 1g orally single dose OR
  
  - Tab. Ciprofloxacin 500mg orally, twice a day for three days to cover chancroid
  
  - Refer to higher centre as early as possible.

**Note**

- A bubo should never be incised and drained at the primary health centre, even if it is fluctuant, as there is a high risk of a fistula formation and chronicity. If bubo becomes fluctuant always refer for aspiration to higher centre.

- In severe cases, surgical intervention may be required for which they should be referred to higher centre.

**Syndrome specific guidelines for partner management**

- Treat all partners who are in contact with client in last 3 months

- Partners should be treated for chancroid and LGV

- Tab Azithromycin 1g orally single dose to cover chancroid

- Cap Doxycycline 100mg orally, twice daily for 21 days to cover LGV

- Advise sexual abstinence during the course of treatment

- Provide condoms, educate on correct and consistent use

- Refer for voluntary counseling and testing for HIV, syphilis and Hepatitis B

- Schedule return visit after 7 days and 21 days

**Management of pregnant partner**

- Quinolones (like ofloxacin, ciprofloxacin), doxycycline, sulfonamides are contraindicated in pregnant women.

- Pregnant and lactating women should be treated with the erythromycin regimen, and consideration should be given to the addition of a parenteral amino glycoside (e.g., gentamicin)

  Tab. Erythromycin base, 500mg orally, 4 times daily for 21 days and refer to higher centre.

  (Erythromycin estolate is contraindicated in pregnancy due to hepatotoxicity. Erythromycin base or erythromycin ethyl succinate should be given)
Causative Organisms
- *Treponema pallidum* (syphilis)
- *Haemophilus ducreyi* (chancroid)
- *Klebsiella granulomatis* (granuloma inguinale)
- *Chlamydia trachomatis* (lymphogranuloma venerum)
- *Herpes simplex* (genital herpes)

History
- Genital ulcer/vesicles
- Burning sensation in the genital region
- Sexual exposure of either partner to high risk practices including oro-genital sex

Examination
- Presence of vesicles
- Presence of genital ulcer- single or multiple
- Associated inguinal lymph node swelling and if present refer to respective flowchart

Lacer characteristics
- Painful vesicles/ulcers, single or multiple - Herpes simplex
- Painless ulcer with shotty lymph node - Syphilis
- Painless ulcer with inguinal lymph nodes - Granuloma inguinale and LGV
- Painful ulcer usually single sometimes - Chancroid associated with painful bubo

Laboratory Investigations
- RPR test for syphilis
- For further investigations refer to higher centre
Guidelines for Setting Up Blood Storage Centres

Treatment
- If vesicles or multiple painful ulcers are present, treat for herpes with Tab. Acyclovir 400mg orally, three times a day for 7 days.
- If vesicles are not seen and only ulcer is seen, treat for syphilis and chancroid and counsel on herpes genitalis.

To cover syphilis give:
- Inj Benzathine penicillin 2.4 million IU IM after test dose in two divided doses (with emergency tray ready).
- Tab Azithromycin 1g orally single dose or
- Tab. Ciprofloxacin 500mg orally, twice a day for three days to cover chancroid.

Treatment should be extended beyond 7 days if ulcers have not epithelialized i.e. formed a new layer of skin over the sore.

Refer to higher centre:
- If not responding to treatment
- Genital ulcers co-existent with HIV
- Recurrent lesion

Syndrome specific guidelines for partner management
- Treat all partners who are in contact with client in last 3 months.
- Partners should be treated for syphilis and chancroid.
- Advise sexual abstinence during the course of treatment.
- Provide condoms, educate about correct and consistent use.
- Refer for voluntary counseling and testing for HIV, Syphilis and Hepatitis B.
- Schedule return visit after 7 days.

Management of Pregnant Women
- Quinolones (like ofloxacin, ciprofloxacin), doxycycline, sulfonamides are contraindicated in pregnant women.
- Pregnant women who test positive for RPR should be considered infected unless adequate treatment is documented in the medical records and sequential serologic antibody titers have declined.
- Inj Benzathine penicillin 2.4 million IU IM after test dose (with emergency tray ready).
- A second dose of benzathine penicillin 2.4 million units IM should be administered 1 week after the initial dose for women who have primary, secondary, or early latent syphilis.
- Pregnant women who are allergic to penicillin should be treated with erythromycin and the neonate should be treated for syphilis after delivery.
- Tab. Erythromycin 500mg orally four times a day for 15 days.
- (Note: Erythromycin estolate is contraindicated in pregnancy because of drug related hepatotoxicity. Only Erythromycin base or erythromycin ethyl succinate should be used in pregnancy.)
- All pregnant women should be asked history of genital herpes and examined carefully for herpetic lesions.
- Women without symptoms or signs of genital herpes or its prodrome can deliver vaginally.
- Women with genital herpetic lesions at the onset of labour should be delivered by caesarean section to prevent neonatal herpes.
- Acyclovir may be administered orally to pregnant women with first episode genital herpes or severe recurrent herpes.
Flowchart: Management of Vaginal Discharge in Females

**SYMPTOMS: VAGINAL DISCHARGE**

- **VAGINITIS**
  - Trichomonas vaginalis (Tv)
  - Candida albicans
  - Gardnerella vaginalis, Mycoplasma causing bacterial vaginosis (Bv)

- **CERVICITIS**
  - Neisseria gonorrhoeae
  - Chlamydia trachomatis
  - Trichomonas vaginalis
  - Herpes simplex virus

**History**
- Menstrual history to rule out pregnancy
- Nature and type of discharge (amount, smell, color, consistency)
- Genital itching
- Burning while passing urine, increased frequency
- Presence of any ulcer, swelling on the vulval or inguinal region
- Genital complaints in sexual partners
- Low backache

**Examination**
- Per speculum examination to differentiate between vaginitis and cervicitis.
  - **A) VAGINITIS**
    - Trichomoniasis - greenish frothy discharge
    - Candidiasis - curdy white discharge
    - Bacterial vaginosis - adherent discharge
    - Mixed infections may present with atypical discharge
  - **B) CERVICITIS**
    - Cervical erosion /cervical ulcer/mucopurulent cervical discharge
    - Bimanual pelvic examination to rule out pelvic inflammatory disease
    - If Speculum examination is not possible or client is hesitant treat both for vaginitis and cervicitis

**Laboratory Investigations (if available)**
- Wet mount microscopy of the discharge for Trichomonas vaginalis and clue cells
- 10% KOH preparation for Candida albicans
- Gram stain of vaginal smear for clue cells seen in bacterial vaginosis
- Gram stain of endocervical smear to detect gonococci
Guidelines for Setting Up Blood Storage Centres

NATIONAL AIDS CONTROL ORGANISATION

Treatment

Vaginitis (TV+BV+Candida)
- Tab. Secnidazole 2gm orally, single dose or
  Tab. Tinidazole 500mg orally, twice daily for 5 days
- Tab. Metoclopramide taken 30 minutes before Tab. Secnidazole, to prevent gastric intolerance
- Treat for candidiasis with Tab Fluconazole 150mg orally single dose or local Clotrimazole 500mg vaginal pessaries once

Treatment for cervical infection (chlamydia and gonorrhea)
- Tab cefixim 400 mg orally, single dose
- Plus Azithromycin 1 gram, 1 hour before lunch. If vomiting within 1 hour, give anti-emetic and repeat
  - If vaginitis and cervicitis are present treat for both
  - Instruct client to avoid douching
  - Pregnancy, diabetes, HIV may also be influencing factors and should be considered in recurrent infections
  - Follow-up after one week

Management in pregnant women
Per speculum examination should be done to rule out pregnancy complications like abortion, premature rupture of membranes

Treatment for vaginitis (TV+BV+Candida)
- Local treatment with Clotrimazole vaginal pessary/cream only for candidiasis. Oral Fluconazole is contraindicated in pregnancy.
  - Metronidazole pessaries or cream intravaginally if trichomoniasis or BV is suspected.
  - Tab. Secnidazole 2gm orally, single dose or
  - Tab. Tinidazole 500mg orally, twice daily for 5 days
  - Tab. Metoclopramide taken 30 minutes before Tab. Metronidazole, to prevent gastric intolerance

Specific guidelines for partner management
- Treat current partner only if no improvement after initial treatment
- If partner is symptomatic, treat client and partner using above protocols
- Advise sexual abstinence during the course of treatment
- Provide condoms, educate about correct and consistent use
- Schedule return visit after 7 days
Flowchart 5.6: Management of Lower Abdominal Pain in Females

**Causative Organisms**
- *Neisseria gonorrhoeae*
- *Chlamydia trachomatis*
- *Mycoplasma, Gardnerella, Anaerobic bacteria (Bacteroides sp., gram positive cocci)*

**History**
- Lower abdominal pain
- Fever
- Vaginal discharge
- Menstrual irregularities like heavy, irregular vaginal bleeding
- Dysmenorrhoea
- Dyspareunia
- Dysuria, tenesmus
- Low backache
- Contraceptive use like IUD

**Examination**
- General examination: temperature, pulse, blood pressure
- Per speculum examination: vaginal/cervical discharge, congestion or ulcers
- Per abdominal examination: lower abdominal tenderness or guarding
- Pelvic examination:
  - Uterine/adnexal tenderness, cervical movement tenderness,

**Laboratory Investigations**
*If available*
- Wet smear examination
- Gram stain for gonorrhea
- Complete blood count and ESR
- Urine microscopy for pus cells

**Differential diagnosis**
- Ectopic pregnancy
- Twisted ovarian cyst
- Ovarian tumor
- Appendicitis
- Abdominal tuberculosis

**Note** A urine pregnancy test should be done in all women suspected of having PID to rule out ectopic pregnancy.
Guidelines for Setting Up Blood Storage Centres

Treatment (Out Client treatment)
In mild or moderate PID (in the absence of tubo ovarian abscess), outClient treatment can be given. Therapy is required to cover *Neisseria gonorrhoeae*, *Chlamydia trachomatis*, and anaerobes.

- Tab. Cefixim 400 mg orally BD for 7 days Tab. Metronidazole 400mg orally, twice daily for 14 days
- Doxycycline, 100mg orally, twice a day for 2 weeks (to treat chlamydial infection)
- Tab. Ibuprofen 400mg orally, three times a day for 3-5 days
- Tab. Ranitidine 150mg orally, twice daily to prevent gastritis
- Remove intra uterine device, if present, under antibiotic cover of 24-48 hours
- Advise abstinence during the course of treatment and educate on correct and consistent use of condoms
- Observe for 3 days. If no improvement (i.e. absence of fever, reduction in abdominal tenderness, reduction in cervical movement, adnexal and uterine tenderness) or if symptoms worsen, refer for inClient treatment.

Caution: PID can be a serious condition. Refer the client to the hospital if she does not respond to treatment within 3 days and even earlier if her condition worsens.

Syndrome specific guidelines for partner management
- Treat all partners in past 2 months
- Treat male partners for urethral discharge (gonorrhea and chlamydia)
- Advise sexual abstinence during the course of treatment
- Provide condoms, educate on correct and consistent use
- Refer for voluntary counseling and testing for HIV, Syphilis and Hepatitis B
- Inform about the complications if left untreated and sequelae
- Schedule return visit after 3 days, 7 days and 14 days to ensure compliance

Management of Pregnant Women
*Though PID is rare in pregnancy,*
- Any pregnant woman suspected to have PID should be referred to district hospital for hospitalization and treated with a parenteral regimen which would be safe in pregnancy.
- Doxycycline is contraindicated in pregnancy.
- Note: Metronidazole is generally not recommended during the first three months of pregnancy. However, it should not be withheld for a severely acute PID, which represents an emergency.

Hospitalization of clients with acute PID should be seriously considered when
- The diagnosis is uncertain
- Surgical emergencies e.g. appendicitis or ectopic pregnancy cannot be excluded
- A pelvic abscess is suspected
- Severe illness precludes management on an outClient basis
- The woman is pregnant
- The client is unable to follow or tolerate an outClient regimen
- The client has failed to respond to outClient therapy

Note: All clients requiring hospitalization should be referred to the district hospital.
Flowchart 5.7: Management of Oral & Anal STIs

Causative Organisms
- Neisseria gonorrhoeae
- Chlamydia trachomatis
- Treponema pallidum (syphilis)
- Haemophilus ducreyi (chancroid)
- Klebsiella granulomatis (granuloma inguinale)
- Herpes simplex (genital herpes)

History of
Unprotected oral sex with pharyngitis.
Unprotected anal sex with anal discharge or tenesmus, diarrhea, blood in stool, abdominal cramping, nausea, bloating

Examination
Look for
- Oral ulceration, redness, pharyngeal inflammation
- Genital or anorectal ulcers single or multiple
- Presence of vesicles
- Rectal pus
- Any other STI syndrome (Do proctoscopy for rectal examination if available)

Laboratory Investigations
- RPR/VDRL for syphilis
- Gram stain examination of rectal swab will show gram negative intracellular diplococcal in case of gonorrhea.
Guidelines for Setting Up Blood Storage Centres

National AIDS Control Organisation

Pharyngitis with history of unprotected oral sex
Or Anal discharge, tenesmus bloating with history of unprotected anal sex
Or Rectal pus or bloating with history of unprotected anal sex

Genital or anorectal ulcers seen
Or Vesicles seen or history of recurrent vesicular eruptions

Diarrhea, blood in stools, abdominal cramping, nausea, bloating with history of unprotected anal sex.

Follow flowchart urethral discharge syndrome and treat accordingly

Follow flowchart genital ulcer syndrome

Tab. Azithromycin 1 gm + Tab. Cefixime 400 mg (Follow urethral discharge syndrome flowchart)
anti-diarrheal medicines as needed
& Refer to higher facility

Any other STI syndrome

Refer to relevant STI Syndromic flow chart
Management of Anogenital Warts

Fig. 5a to c: Anogenital Warts

Fig 5a: Perivulval warts

Fig 5b: Penile warts

Fig 5c: Perianal warts
Causative Organism

Virus: Human Papilloma Virus (HPV)

Clinical features

Single or multiple soft, painless, pink in color, “cauliflower” like growths which appear around the anus, vulvo-vaginal area, penis, urethra and peri-aneum. Warts could appear in other forms such as papules which may be keratinized.

Diagnosis

Presumptive diagnosis by history of exposure followed by signs and symptoms.

Differential diagnosis

i. Condyloma lata of syphilis
ii. Molluscum contagiosum

Treatment

Recommended regimens:

Penile and Perianal warts

- 20% Podophyllin in compound tincture of benzoin applied to the warts, while carefully protecting the surrounding area with Vaseline, to be washed off after 3 hours. It should not be used on extensive areas per session.

- Treatment should be repeated weekly till the lesions resolve completely.

Note: Podophyllin is contra-indicated in pregnancy. Treatment should be given under medical supervision. Clients should be warned against self-medication.

Cervical warts

- Podophyllin is contra-indicated.
- Biopsy of warts to rule out malignant change.
- Cryo cauterization is the treatment of choice.
- Cervical cytology should be periodically done in the sexual partner(s) of men with genital warts.
Management of Molluscum contagiosum and Ectoparasitic infestation

Causative Organism
Pox virus

Clinical features
Multiple, smooth, glistening, globular papules of varying size from a pinhead to a split pea can appear anywhere on the body. Sexually transmitted lesions on or around genitals can be seen. The lesions are not painful except when secondary infection sets in. When the lesions are squeezed, a cheesy material comes out.

Diagnosis
Diagnosis is based on the above clinical features.

Treatment
• Individual lesions usually regress without treatment in 9-12 months.
• Each lesion should be thoroughly opened with a fine needle or scalpel. The contents should be exposed and the inner wall touched with 25% phenol solution or 30% trichloracetic acid.

Pediculosis pubis

Causative Organism
Lice - Phthirus pubis

Scabies

Causative Organism  Mite - Sarcoptes Scabiei.

Clinical features
There may be small red papules with a tiny central clot caused by lice irritation. General or local urticaria with skin thickening may or may not be present. Eczema and Impetigo may be present.

Treatment
Recommended regimen:
• Permethrin 1% creme rinse applied to affected areas and wash off after 10 minutes

Special instructions
• Retreatment is indicated after 7 days if lice are found or eggs observed at the hair-skin junction.
• Clothing or bed linen that may have been contaminated by the client should be washed and well dried or dry cleaned.
• Sexual partner must also be treated along the same lines.
Clinical features

Severe pruritis (itching) is experienced by the client, which becomes worse at night. Other members of family also affected (apart from sexual transmission to the partner, other members may get infected through contact with infected clothes, linen or towels).

Complications

- Eczematization with or without secondary infection
- Urticaria
- Glomerulonephritis
- Contact dermatitis to antiscabietic drug

Diagnosis

The burrow is the diagnostic sign. It can be seen as a slightly elevated grayish dotted line in the skin, best seen in the soft part of the skin.

Treatment

Recommended regimens:

- Permethrin cream (5%) applied to all areas of the body from the neck down and washed off after 8—14 hours.
- Benzyl benzoate 25% lotion, to be applied all over the body, below the neck, after a bath, for two consecutive nights. Client should bathe in the morning, and have a change of clothing. Bed linen is to be disinfected.

Special instructions

- Clothing or bed linen that have been used by the client should be thoroughly washed and well dried or dry cleaned.
- Sexual partner must also be treated along the same lines at the same time.

Partner management

Timely partner management serves following purpose:

- Prevention of re-infection
- Prevention of transmission from infected partners and
- Help in detection of asymptomatic individuals, who do not seek treatment.

Critical issues on partner management

- Confidentiality Partners should be assured of confidentiality. Many times partners do not seek services, as they perceive confidentiality as a serious problem. Respecting dignity of client and ensuring confidentiality will promote partner management.

- Voluntary reporting Providers must not impose any pre-conditions giving treatment to the index client. Providers may need to counsel client several times to emphasize the importance of client initiated referral of the partners.

- Client initiated partner management Providers should understand that because of prevailing gender inequities, women may not be in position always to communicate to their partners regarding need for partner management. Such client imitated partner management may not work in some relationships and may also put women at the risk of violence. Hence alternative approaches should be considered in such situations.
• **Availability of services** RTI/STI diagnostic and treatment services should be available to all partners. This may mean finding ways to avoid long waiting times. This is important because many asymptomatic partners are reluctant to wait or pay for services when they feel healthy.

**Approaches for partner management**
There are two approaches to partner management:

i. **Referral by index client**
   In this approach, index client informs the partner/s of possible infection. This appears to be a feasible approach, because it does not involve extra personnel, is inexpensive and does not require any identification of partners. A partner notification card with relevant diagnostic code should be given to each index client, where partner management is indicated. This approach may also include use of client initiated therapy for all contacts.

ii. **Referral by providers**
   In this approach service provider contacts client’s partners through issuing appropriate partner notification card. The information provided by client is used confidentially to trace and contact partners directly. This approach needs extra staff and is expensive.

---

**Box 5.1: Coupon for a free examination**

**Coupon for a free examination**

<table>
<thead>
<tr>
<th>Date:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Please attend following centers along with the card</td>
</tr>
<tr>
<td>Stamp of the Facility</td>
</tr>
<tr>
<td>Timings:</td>
</tr>
<tr>
<td>Diagnostic Code:</td>
</tr>
</tbody>
</table>

**Sample Partner reporting card**

**Note**

| o s e s r a e g c a n e s h e r e c l i e n t s a r e i r s a s e o c o n a c t a r n e r s h e n s e m s n o r s o s e i l l e n c e o r o e s | 
| c l i n i c o r h e a l h e a r m e n s a c a n a e m o r r a c e h e c o n a c r e a m e n | 

**General principles for partner management**

- In general, partners should be treated for the same STI as the index client, whether or not they have symptoms or signs of infection.
- Health care providers should be as sure as possible about the presence of an STI before informing and treating the partner, and should remember that other explanations are possible for most RTI symptoms like vaginal discharge.
- Special care is required in notifying partners of women with lower abdominal pain who are being treated for possible pelvic inflammatory disease. Because of the serious potential complications of PID (infertility, ectopic pregnancy), partners should be treated to prevent possible re-infection. It should be recognized, however, that the diagnosis of PID on clinical grounds is inaccurate, and the couple should be adequately counseled about this uncertainty. It is usually better to offer treatment as a precaution to preserve future fertility than to mislabel someone as having an STI when they may not have one.

**Follow-up visits**

Follow-up visits should be advised

- To see reports of tests done for HIV, Syphilis and Hepatitis B.
• If symptoms persist, advise clients to come back for follow up after 7 days. In case of PID, follow up should be done after 2 to 3 days.

Management of treatment failure and reinfection

When clients with an RTI/STI do not respond to treatment, it is usually because of either treatment failure or re-infection. Ask the following questions to ascertain the cause:

To probe for treatment failure

• Did you take all your medicines as directed?
• Did you share your medicine with anyone, or stop taking medicines after feeling some improvement?
• Was treatment based on the national treatment guidelines? Also consider the possibility of drug resistance if cases of treatment failure are showing an increasing trend.

To probe for reinfection

• Did your partner(s) come for treatment?
• Did you use condoms or abstain from sex after starting treatment?

Note: Recurrence is also common in endogenous vaginal infections, especially when underlying reasons (douching, vaginal drying agents, diabetes mellitus, hormonal contraceptives) are not addressed.

Box 5.2: Management of treatment failure and reinfection

For treatment failure

All cases of treatment failures should be referred to higher health facility.

For reinfection

• Consider re-treatment with same antibiotics.
• Refer to higher health facility if symptoms persist.

Screening for Asymptomatic Clients

It is well known that most RTIs/STIs are asymptomatic, especially amongst the women. The case finding is a process of opportunistic screening for an infection at the time when an individual presents to a health facility, regardless of presence of symptoms. Case findings opportunities are most commonly seen while providing services for contraception. Providers should use opportunities for potential contraceptive clients to screen for RTIs/STIs. The National Guidelines for IUD, Oral Pills, National Standards for Sterilization Services provide detailed guidelines regarding screening of RTIs/STIs.

Similar opportunities exist in pregnancy care settings. Most common screening programmes worldwide are those for detecting syphilis in pregnant women. Untreated syphilis in pregnant female is associated with number of adverse outcomes such as pregnancy loss, stillbirths and congenital syphilis. Providers are recommended to follow Government of India’s following guidelines while providing services to pregnant women:

2. Guidelines for Ante-Natal Care and Skilled Attendance at Birth by ANMs and LHVs, 2006.
Sexually Transmitted Infections (RTIs) among children and adolescents

Reproductive tract infections in children are acquired through three different ways (i) transplacental transmission occurring in utero, intrapartum transmission (during labour and delivery) e.g. syphilis, HIV, cytomegalovirus (CMV) and human papilloma virus infection (HPV); (ii) postnatal transmission (during breastfeeding, accidental and through sexual abuse) (iii) due to sexual abuse or in sexually active adolescents who are at risk.

Child sexual abuse is the use of a child as an object of gratification for adult sexual needs or desire. The common sexual abuse encountered by girls is genital contact, masturbation, vaginal, oral or anal intercourse by a male perpetrator, while boys are subjected to fellatio and anal intercourse.

Adolescents and youth in the age group 10-24 years contribute to about 30% of our population. The data from various Indian studies reveal that adolescents indulge in pre-marital sex more frequently and at an early age. STIs, including HIV, are most common among young people aged 15-24 years and more so in young women. The physiological risk of increased susceptibility to infections among adolescent girls is due to the presence of greater cervical ectopy which makes the cervix more susceptible to gonorrhea, chlamydia and HPV. Adolescents today face enhanced vulnerability to unwanted pregnancy and STIs including HIV/AIDS. Studies from African countries suggest that girls marrying at an early age are at high risk of HIV infections. Many interrelated and complex factors that put adolescents at risk of STIs include poor education, unemployment and poverty. Urbanization tends to disrupt family relationships, social networks and traditional values while generating more opportunity for sexual encounters. Lack of information about sexual matters, as well as STI prevention, symptoms and treatment also put both male and female adolescents at risk of STIs. Even when adolescents have accurate knowledge about STDs, some incorrectly perceive their risk as low either due to familiarity with a sexual partner or as relationship matures or simply because they are passing through a stage of life in which risk taking is particularly attractive especially under the strong influence of their peers, migration and displacement, multiple and concurrent sexual partnership, lack of access to effective and affordable STI services. Therefore there is an urgent need for improving the accessibility of adolescents to preventive and curative services including information and counseling.
In the RCH 2, Adolescent Reproductive and Sexual Health (ARSH) Strategy is to be implemented in the primary health care setting based on the implementation Guide for state and district program managers. Under this strategy, it is expected that a core package of promotive, preventive, curative, counseling, referral and outreach services would be provided through the public health care facilities. It states that services for adolescents must demonstrate relevance to the needs and wishes of the young people.

Clinical presentation of RTIs/STIs in children and adolescents

The presenting symptoms of adolescents is very peculiar as very often they present with symptoms other than those of RTI/STI. Therefore risk assessment plays a crucial role. The increasing tendency of homosexual behavior as reported by some studies must also be kept in mind and anogenital lesions must be looked for.

Girls

- In general, endogenous vaginitis rather than an STI is the main cause of vaginal discharge among adolescent females.
- Approximately 85% of gonococcal infection in females will be asymptomatic. However, there may be vulval itching, minor discharge, urethritis or proctitis. In pre-pubescent girls, a purulent vulavo-vaginitis may occur.
- Similarly, Chlamydia trachomatis infection is asymptomatic in the majority of cases. Symptoms that may occur in the adolescent are intermenstrual bleeding, postcoital bleeding and an increase in vaginal secretions.
- Candida albicans is uncommon in adolescents prior to puberty. If present, the adolescent may have a discharge, vulval itching, dyspareunia, peri-anal soreness or a fissuring at the introitus. Attacks of candida vulvitis may be cyclical in nature and corresponds to menstruation.
- Bacterial vaginosis does not produce vulvitis and the adolescent will not complain of itching or soreness.
- The signs of acquired syphilis in children present with small chancres or mucocutaneous moist lesions either on the vulva or anus. Presentation of syphilis is the same in adolescents and adults.

Boys

- Gonorrhea among boys presents as proctitis, urethral discharge, asymptomatic pyuria, penile edema, epididymitis and testicular swelling. Disseminated gonorrhea presents with multiple systemic manifestations.
- Chlamydia in males presents as urethritis.

.2 Sexually Transmitted Infections (STIs) among Sex Workers and MSMs

In some groups of population with high risk practices such as sex workers, men having sex with men and intravenous drug users, the prevalence of STIs and HIV is higher than the general population. Treating these clients early and appropriately will reduce risk of HIV infection and if already infected, they can be advised for seeking the available
services at the integrated testing and counseling facilities for knowing of HIV status and further follow up action as indicated. It is desirable that all clients with risky behaviour are tested.

6.3 Clinical Management of STI in Most at Risk Groups

High rates of curable STIs have been observed worldwide in commercial sex settings where condom use rates are low and access to effective STI treatment services is limited.

Effective prevention and treatment of STIs among female sex workers requires attention to both symptomatic and asymptomatic infections. The prevention and treatment of STIs in female sex workers in STI clinics should have the following two components:

- **Treatment of Symptomatic Infections**
  - As per the flow charts included in these guidelines.

- **Screening and Treatment of Asymptomatic Infections**
  - Periodic history taking, clinical examination and simple laboratory diagnostics (where available);
  - Periodic presumptive treatment for asymptomatic gonococcal and chlamydial infections (in areas with high STI rates and minimal STI services); and
  - Semi-annual serologic screening for syphilis.

Female sex workers should be encouraged to attend the clinic for routine check-ups. During the visit, the clinic staff should take a detailed history and perform an examination. In addition, even if there is no evidence of infection, treatment is recommended if:

- the sex worker is visiting the clinic for the first time;
- six months have passed since the sex worker last received treatment.

The rationale for presumptively treating sex workers who are asymptomatic is that they are frequently exposed to STIs and they often do not show signs or symptoms even when infected. A sex worker is likely to be exposed and infected with a STI, if the time lapse is more since her last treatment. (Note: This recommendation will be reviewed and revised as data on the epidemiology of STIs among sex workers become available).

It is anticipated as STI prevalence falls, periodic presumptive treatment of asymptomatic STI treatment among sex workers will be tapered to first visit asymptomatic treatment under the following conditions:

- Evidence of low gonococcal and chlamydial infections (10% and below);
- High condom use among sex workers (>70%); and
- High quality STI services for sex workers have been established, with almost 80% of sex workers having access to STI services (80% provided with asymptomatic treatment at least once and are coming to the clinic for regular STI screening).

In such situations, regular visits for routine examination and counseling should be promoted. Sex workers should be counseled at every opportunity (in the clinic and in the community) on the
importance of using condoms. Peer educators, outreach workers and clinic staff should reinforce the following message to sex workers visiting the clinic:

- The only reliable way to protect oneself from HIV and STIs is to use condoms consistently and correctly; and
- Antibiotics dispensed at the clinic are effective only for the few curable STIs.

Outreach staff should also remind sex workers about their clinic appointments and help them keep their appointments.

It is also important to cater for STI management needs of MSM population groups. Emergence of anal STIs is cause of concern. Service providers should be sensitive to the needs of the MSM population groups and counsel them about risk reduction, use of condoms and HIV testing.

**Flowchart**. Management of STIs during routine visit by female sex workers

---

**Clinic visit by sex worker**

1. **First visit to clinic or due for presumptive treatment?**
   - **Yes**
     - **Unprotected sex**
     - **No**

2. **With partner with STIs?**
   - **Yes**
   - **Give treatment according to partner’s symptoms**
   - **No**

3. **Take history**

4. **Examine Client (external genital, speculum, and bimanual examination)**

5. **Draw blood and send to referral laboratory for syphilis test every 6 months**

6. **Look for signs of STI on exam**

7. **Genital or anorectal ulcers?**
   - **Yes**
     - **Bimanual Lower abdominal or cervical motion tenderness?**
     - **Yes**
       - **Treat according to the lower abdominal pain flowchart**
     - **No**
       - **Treat for gonorrhoea and chlamydia**
   - **No**

8. **Mucopurulent discharge or red cervix?**
   - **Yes**
     - **Treat for gonorrhoea and chlamydia**
   - **No**

9. **Visible vaginal discharge?**
   - **Yes**
     - **Treat according to vaginal discharge flowchart**
   - **No**

---

**Notes**:

a. Without condom or condom failure
b. All currently active sex workers have positive risk assessment and should be treated for gonococcal and chlamydial cervicitis.
Flowchart 2: Flowchart for routine visit by male and transgender sex workers in clinics

Clinic visit by client

Take history

First visit to clinic or due for presumptive treatment?

Yes

Treat for gonorrhoea and chlamydia

No

Unprotected sex with partner with STI?

Yes

Give treatment according to partner’s symptoms

No

Pharyngitis with history of unprotected oral sex?

Yes

Treat for gonorrhoea and chlamydia

No

Anal discharge or tenesmus?

Yes

Treat for gonorrhoea and chlamydia

No

Diarrhea, blood in stools, abdominal cramps, nausea, bloating?

Yes

Treat for gonorrhoea and chlamydia + anti-diarrheal medicines as needed

No

Examine Client (oral, external anogenital, digital rectal, proctoscope)²

Look for signs of STI on exam

Yes

Treat according to the genital ulcer flowchart

No

Genital or anorectal ulcers?

Yes

Treat for gonorrhoea and chlamydia

No

Rectal pus?

Yes

Treat for gonorrhoea and chlamydia

No

Urethral discharge?

Yes

Treat according to the urethral discharge flowchart

No

Draw blood and send to referral laboratory for syphilis test every 6 months

a. Without condom or condom failure
b. If asymptomatic, conduct digital rectal and proctoscope exam only if acceptable.
Management of Sexual Violence

Sexual violence is defined as “any sexual act, attempt to obtain a sexual act, unwanted sexual comments or advances, or acts to traffic women’s sexuality, using coercion, threats of harm or physical force, by any person regardless of relationship to the victim, in any setting, including but not limited to home and work”. Often, because the victims feel uncomfortable talking about sexual violence, they may come to the clinic with other non-specific complaints or requesting a check-up, assuming that the health care provider will notice anything abnormal that needs treatment. Therefore, health care workers should maintain a high index of suspicion and ask about experience of sexual violence or abuse. The following services should be available, on-site or through referral, for clients who have experienced sexual violence:

A. Visual inspection

Before proceeding for examination consent of the victim or the legal guardian in case of minors must be taken. Counseling of the victim must be done. Examination of clothes, injuries and genital must be carried out. Look for bleeding, discharge, odour, irritation, warts and ulcerative lesions.

B. Collection of forensic evidence

Forensic examination should be available to document evidence if the person chooses to take legal action.

Staff should be trained in how to take forensic specimens, or referral links should be made. Forensic examination must include physical and genital examination. (Refer to the State-specific guidelines for forensic examination).

C. Collection of samples for detecting STIs

If facilities permit, swabs must be collected from various sites for wet mount examination or culture of a number of causative organisms. Blood could be collected for VDRL/RPR, HIV and HbsAg tests.

D. Essential medical care for injuries and health problems

Medical management includes

i. Prevention of pregnancy by offering emergency contraception

ii. STI prophylaxis

iii. Care of injuries

Note

Essential medical care for injuries and health problems would consist of:

- Post exposure prophylaxis against pregnancy

Emergency Contraception (EC) to prevent unwanted pregnancy should be given within 72 hrs of unprotected sexual intercourse.
**Box 7. Post exposure prophylaxis with Emergency contraceptives**

<table>
<thead>
<tr>
<th>Type of Emergency contraception</th>
<th>First dose (within 72 hours after unprotected intercourse)</th>
<th>Second dose (2 hours later)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levonorgestrel-only pills for emergency contraception</td>
<td>Levonorgestrel in 2 doses First dose of 0.75 mg of levonorgestrel</td>
<td>Repeat same dose after 12 hrs</td>
</tr>
</tbody>
</table>

**Post exposure prophylaxis of STI**

STI prophylaxis should be started as early as possible, although the doses should be spread out (and taken with food) to reduce side-effects such as nausea.

**Box 7.2 Post exposure prophylaxis of STI for adults and older children and adolescents weighing more than 45 kg**

1. **For protection against syphilis, gonorrhea and chlamydia**
   - Tab. Azithromycin 1gm orally, single dose under supervision PLUS
   - Tab. Cefixine 400mg orally single dose

2. **For protection against T. vaginalis**
   - Tab Metronidazole 2gm single dose
   - Tab Tinidazole 2gm single dose

**Box 7.3 Post exposure prophylaxis of STI for children**

1. **For protection against syphilis and chlamydia**
   - Erythromycin 12.5 mg/kg of body weight orally 4 times a day for 14 days

2. **For protection against gonorrhea**
   - Cefixime 8 mg/kg of body weight as a single dose, or
   - Ceftriaxone 125 mg by intramuscular injection

3. **For protection against T. vaginalis**
   - Metronidazole 5 mg/kg of body weight orally 3 times a day for 7 days
• **Post exposure prophylaxis of HI**
  - Refer to district hospital and follow NACO guidelines for the same.

• **Post exposure prophylaxis against Hepatitis B**
  - If not vaccinated earlier, it is recommended. If vaccine is not available, refer to the centre where Hepatitis B vaccination facilities are available.

A. **Psychosocial support (both at time of crisis and long term)**

Psychosocial management includes counseling and supportive services, which should be available on-site or by referral. Women or children who have been sexually abused may need shelter and legal protection. Adolescents in particular may need crisis support, as they may not be able or willing to disclose the assault to parents or care takers.

B. **Follow-up services for all of the above**

It is essential to explain the importance of follow-up appointments and services during the first visit itself. The woman should be clearly told whom to contact if she has other questions or subsequent physical or emotional problems related to the incident.
Effective communication of information on prevention, especially on behavior change, linked with effective treatment is a key to the control of RTIs/STIs. When clear communication is linked to effective treatment there can be additional benefits. Even when treatment is not available at outreach RCH service delivery settings, prevention information and condoms can be provided. Effective communication can be done in the following ways:

**Guidelines for counseling**

a) Welcome your client warmly by name and introduce yourself.
b) Sit closely enough so that you can talk comfortably and privately.
c) Make eye contact and look at the client as s/he speaks.
d) Use language that the client understands.
e) Listen and take note of the client’s body language (posture, facial expression, looking away, etc.). Seek to understand feelings, experiences and points of view.
f) Be encouraging. (Nod or say, “Tell me more about that.”)
g) Use open-ended questions.
h) Provide relevant information.
i) Try to identify the client’s real concerns.
j) Provide various options for the client.
k) Respect the client’s choices.
l) Always verify that the client has understood what has been discussed by having the client repeat back the most important messages or instructions.

**Barriers to good counseling**

- Lack of privacy.
• Not greeting or not looking at the client.

• Appearing to be distracted (for example, by looking at your watch or reading papers while s/he is talking).

• Using a harsh tone of voice or making angry gestures.

• Sitting while the client stands or sitting far away from the client.

• Allowing interruptions during the consultation.

• Being critical, judgmental, sarcastic or rude.

• Interrupting the client.

• Making the client wait for a long time.

• Not allowing enough time for the visit.

**Client counseling on RTIs STIs** During counseling session, provider should talk about causation, transmission, recommended treatment, prevention, risk reduction, behavior change, and partner referral. Clinics can have take away information brochures in simple languages with illustrations to reinforce messages.

**Goals of client education and counselling**

• Primary prevention or preventing infection in uninfected clients. This is the most effective strategy to reduce the spread of RTIs/STIs and can be easily integrated into all health care settings.

• Curing the current infection.

• Secondary prevention, which prevents further transmission of that infection in the community and prevents complications and re-infection in the client.

**What the client needs to** 

**Prevention of RTIs STIs**

• Risk reduction

• Using condoms, correctly and consistently, availability of condoms

• Limiting the number of partners

• Alternatives to penetrative sex

• Negotiating skills

**Information about RTIs STIs**

• How they are spread between people

• Consequences of RTIs/STIs

• Links between RTIs/STIs and HIV

• RTI/STI Symptoms - what to look for and what symptoms mean

**RTI STI Treatment**

• How to take medications

• Signs that call for a return visit to the clinic

• Importance of partner referral and treatment

• Acknowledge gender inequalities which may impact male partners coming forward to seek services

**Principles of effective client education**

• Shows respect and concern for the safety of clients through body language, telling clients you are concerned, being attentive to and acknowledging clients’ feelings, and taking more time with them.

• Is client-centered. Provides
messages that are tailored for each individual—different messages for married men, women, and adolescents.

- Involves 3 kinds of learning: through ideas, actions, and feelings (cognitive, psycho-motor, and affective).
- Uses multiple channels (eyes, ears and face-to-face/visual, auditory, interpersonal). Delivers messages via the eyes, ears, and face-to-face communication.

**Integrated Counselling and Testing Centers (ICTC) and their role in STI prevention and Management**

Clients with STI have shown high risk sexual behavior. Based on this high risk behavior, the health care worker should inform the Client about the links between STIs and HIV and should encourage all Clients to undergo an HIV test as the risk of HIV among STD is upto 10 times higher. In order to get HIV test, Integrated counseling and testing centers (ICTC) have been established. Each ICTC has counselor(s) and a laboratory technician.

As of November 2006, there are 3394 counseling centers and more are being established. ICTCs are located in the medical colleges, district hospitals in all states and in addition in selected CHCs and PHCs especially in the high prevalence states. It is envisaged to establish ICTCs at all CHC and additional at selected PHCs in all states.

In Integrated Counseling and Testing Centers the STI Client will receive comprehensive and accurate information on HIV/AIDS and HIV counseling to facilitate an informed choice regarding an HIV test. The integrated centers serve as single window system by pooling all Counselors and Lab Technicians working in ICTC, PPTCT, Blood Safety, STI, ART/OIs and HIV - TB together to offer round the clock counseling and testing services. This common facility will remove fear, stigma and discrimination among the clients and Clients, PLHAs and the referrals.

The ICTC have common television and video based health education materials that are screened continuously in the Clients waiting area. The information related to preventive, promotive and curative health care along with information regarding HIV/AIDS, and various services provided by the hospital is provided to all the Clients.

Further two strategies are adopted in ICTC for HIV testing.

- **Opt-out strategy** In this, the counselor “assumes” that the Client has come to get an HIV test (implied consent). The HIV test will be done unless the Client actively denies the test.

- **Opt-in strategy** In this, the counselor specifically asks the client, whether s/he would like to undergo the HIV test. The client has to actively agree to the HIV test.

As per the National AIDS Prevention and Control Policy, all HIV tests are voluntary, based on the clients consent, accompanied by counseling and confidentiality of the results.

**Aims of Pre-test counseling**

- To ensure that any decision to take the test is fully informed & voluntary
- To prepare the client for any type of result, whether negative or positive or indeterminate
To provide client risk reduction information & strategies irrespective of whether testing proceeds

The Clients are advised about preventive measures and use of condoms.

If the Client declines to take the test, he/she leaves the ICTC. Some Clients return to the ICTC after a few days for the test. If the client agrees to undergo the test, he/she proceeds to the attached laboratory for blood collection. After the blood sample is taken, the client either waits for the results or is asked to return on assigned date with Patient Identification Digit (PID) number

The tests are performed by using the rapid test kits. If the test is negative and the client has history of high risk factors, he/she is advised to repeat the test after 3 months as he/she may be in the window period. If the result is positive the test is repeated with kits using a different method of antibody detection. The result is considered positive if all three tests are positive. Before the results are revealed to the client, post counseling is done.

Aims of Post-test counseling aims to

- Help client understand and cope with the HIV test results
- Provide the client with any further information required
- Help Clients decide what to do about disclosing their test result to partners and others
- Help Clients reduce their risk of HIV/AIDS and take action to prevent infection to others including condom, avoiding multiple partners and other high risk behaviour (Positive prevention).
- Help Clients access the medical and social care and support they need
- Establish link with PLHA groups, if needed

In STI settings, the following is recommended

(i) HIV testing should be recommended for all STIs Clients after pre-test counseling and informed consent. There should be guarantee for confidentiality. HIV counseling and testing can either be performed in the STI clinic (if counselor is available) or Clients can be referred to the nearest ICTC.

(ii) In some cases of STIs in the presence of HIV infection, larger doses and longer treatment duration of the drugs listed under the different STIs may be required. These Clients should be followed up regularly for longer duration.

(iii) Excessive use of anti-microbials should be avoided, as it is likely to lead to more rapid development of antibiotic resistance.

(iv) Although counseling of individual Clients on risk reduction, and prevention of STI transmission to the partners should be done in all Clients of STI, this is of vital importance for those infected with HIV.
LABORATORY TESTS FOR RTIs/STIs

Laboratory tests improve the diagnostic sensitivity and specificity of symptomatic RTIs/STIs, particularly in women, to differentiate serious infections, i.e., cervicitis, from milder but more common infections, i.e., vaginitis. Simple laboratory tests incorporated in syndromic management of urethral discharge also help distinguish between mixed and single infections, reducing the administration of unnecessary antibiotics. The tests also help in detection of infections in asymptomatic individuals, specifically in female Clients, who carry the burden of RTIs/STIs complications and sequelae. Laboratory testing is even more important in pregnant women to prevent the adverse consequences of syphilis, gonococcal and chlamydial infection in newborns.

Laboratory diagnosis of RTIs includes three major equally important steps i.e.; collection of specimen, its transport and use of a reasonable sensitive and specific test. Laboratory procedures at PHC level should include microscopic examination of fresh and stained specimens. Microscopic examination of urethral discharge helps to single out nongonococcal infection. Wet mount microscopy in vaginal discharge helps to detect trichomoniasis, (Trichomonas vaginalis) candidiasis and bacterial vaginosis (BV). Simple additional tests to identify bacterial vaginosis are the KOH sniff test and measurement of pH of vaginal fluid. Lab procedures may also include simple nontreponemal syphilis screening tests: rapid plasma reagin (RPR) or Venereal Disease Research Laboratory (VDRL).

Effective diagnosis of vaginitis by vaginal pH, amine test and wet smear of vaginal smear can be achieved with a sensitivity of 75-80%. The sensitivity of detecting candida organisms by 10% KOH preparation, saline microscopy and Gram stain is 70%, 40-60% and 65% respectively. The sensitivity of wet mount to identify trichomonsads in symptomatic women is approximately 80% while it decreases to 50% in asymptomatic women. The sensitivity of papanicolaou (PAP) smear for T. vaginalis is around 60%. Gram stain is more reliable than PAP for diagnosis of BV infection. For other RTIs/STIs, it is advisable to use ELISA based assays or molecular diagnostics to achieve good sensitivity and specificity.

vaginal pH

The pH of vaginal fluid should be measured using pH paper of appropriate range (3.8
to 6.0). The vaginal fluid sample is collected with a swab from the lateral and posterior fornices of the vagina and the swab is then touched directly on to the paper strip. Alternatively, the pH paper can be touched to the tip of the speculum after it has been withdrawn from the vagina. Care must be taken not to use any jelly (eg K. jelly) or disinfectant (eg.savlon) before doing pH test. Contact with cervical mucus must be avoided since it has a higher pH. The normal vaginal pH is 4.0. In BV, the pH is generally elevated to more than 4.5.

The vaginal pH test has the highest sensitivity (true negative) of the four characteristics used for identification of BV, but the lowest specificity (true positive); an elevated pH is also observed if the vaginal fluid is contaminated with menstrual blood, cervical mucus or semen, and in women with a *T. vaginalis* infection. In simple words it means that if pH test is negative the result can be taken as it is but if it is positive one has to rule out the other factors contaminating the sample such as menstrual blood, cervical mucus or semen or presence of *T. vaginalis* infection

**Wet mount microscopy**

Wet mount microscopy is the direct microscopic examination of vaginal discharge for the diagnosis of trichomoniasis, candidiasis and BV.

<table>
<thead>
<tr>
<th>Collect specimen</th>
<th>Take a specimen of discharge with a spatula from the side walls or deep in the vagina where discharge accumulates.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prepare slide</td>
<td>Mix specimen with 1 or 2 drops of saline on a glass slide and cover with a cover slip.</td>
</tr>
</tbody>
</table>
| What to look for | • Examine at 100X magnification and look for typical jerky movement of motile trichomonads (ovoid, globular, pear-shaped flagellated protozoan).  
• Examine at 400X magnification to look for yeast cells (round to ovoid cells with typical budding) and trichomonads.  
• To make identification of yeast cells easier in wet mount slides, mix the vaginal swab in another drop of saline and add a drop of 10% potassium hydroxide to dissolve other cells and note any fishy odour.  
• Presence of clue cells (squamous epithelial cells covered with many small coccobacillary organisms). Wet mount shows stippled granular cells without clearly defined edges because of the large numbers of adherent bacteria present and an apparent disintegration of the cells. The adhering bacteria are predominantly *vaginalis*, sometimes mixed with anaerobes). |
| Important        | Look for evidence of other vaginal or cervical infections as multiple infections are common. |
Fig A1b: Potassium hydroxide preparation of vaginal fluid showing budding yeast and mycelia

Fig A1c: "Clue cells" in vaginal wet mount (x 400)

Fig A1d: Trichomonas vaginalis in a wet mount of vaginal discharge (x 400)
Box A.2 Clinical criteria for Bacterial vaginosis (BV)

BV can be diagnosed using simple clinical criteria with or without the aid of a microscope.

<table>
<thead>
<tr>
<th>Collect specimen</th>
<th>Note color and consistency of discharge. Take a specimen of discharge from the side walls or deep in the vagina where discharge pools (or use discharge remaining on speculum). Touch pH paper to discharge on swab or speculum and note pH.</th>
</tr>
</thead>
</table>
| Prepare slide    | • Place specimen on a glass slide. Add a drop of 10% potassium hydroxide (KOH) and note for any fishy smell.  
• Make a wet smear with 0.9% normal saline, cover with coverslip and see under microscope for clue cells. |
| What to look for | The diagnosis of BV is based on the presence of at least 3 of the 4 following characteristics  
• Homogeneous white-grey discharge that sticks to the vaginal walls  
• Vaginal fluid pH >4.5  
• Release of fishy amine odour from the vaginal fluid when mixed with 10% potassium hydroxide (positive whiff test) “Clue cells” visible on microscopy on wet preparation |
| Important        | Look for evidence of other vaginal or cervical infections as multiple infections are common. |

**Whiff test**

Women with BV often complain of a foul vaginal smell. This odour is due to the release of amines, produced by decarboxylation of the amino acids lysine and arginine by anaerobic bacteria. When potassium hydroxide is added to the vaginal fluid, these amines immediately become volatile, producing the typical fishy odour.

Place a drop of vaginal fluid on a glass slide and add a drop of 10% potassium hydroxide. Hold the slide close to nose to detect the amine odour. After a positive reaction, upon standing the specimen will quickly become odourless because the amines will be rapidly and completely volatilized.

**Gram stain microscopy**

A gram stain of a vaginal smear has a higher specificity for the detection of clue cells than a wet mount preparation. Moreover, a Gram stain allows good evaluation of the vaginal bacterial flora. Normal vaginal fluid contains predominantly Lactobacillus
species and exceedingly low numbers of streptococci and coryneform bacteria. In BV, lactobacilli are replaced by a mixed flora of anaerobic bacterial morphotypes and *G. vaginalis*. However, gram stain microscopy has a very low sensitivity for detecting gonorrhea among women; culture remains the method of choice.

For men, gram stain microscopy of urethral discharge smear will show gram-negative intracellular diplococci in case of gonorrhea. In case of non-gonococcal urethritis more than 5 neutrophils per oil immersion field (1000X) in the urethral smear or more than 10 neutrophils per high power field in the sediment of the first void urine are observed.

**Box A . Gram stain microscopy of vaginal smears**

<table>
<thead>
<tr>
<th>Collect specimen</th>
<th>A Gram stain slide can be prepared at the same time as the wet mount by rolling the spatula/swab on a separate slide.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2. Stain with crystal violet (60 seconds) and rinse.</td>
</tr>
<tr>
<td></td>
<td>3. Stain with iodine (60 seconds) and rinse.</td>
</tr>
<tr>
<td></td>
<td>4. Decolorize with acetone-ethanol for few seconds (until the liquid runs clear).</td>
</tr>
<tr>
<td></td>
<td>5. Stain with safranin (60 seconds) and rinse.</td>
</tr>
<tr>
<td></td>
<td>6. Gently blot dry and examine under oil immersion (1000X) and count each type of organisms.</td>
</tr>
</tbody>
</table>

**What to look for**

1. Lactobacilli only: Normal
2. Mixed flora, mainly lactobacilli with a few short rods (coccobacilli): Considered normal
3. Presence of clue cells; mixed flora, mainly Gardnerella and anaerobic bacteria with a few lactobacilli diagnose as BV
4. Presence of clue cells, mixed flora of Gram-positive, Gram-negative and Gram-variable rods; no lactobacilli diagnose as BV
5. Count each type of organism and use the Nugent score to record the infection.

**Important**

Look for evidence of other vaginal or cervical infections as multiple infections are common.
## Box A. Nugent score

**Scoring system (0 to 10) from Gram stained vaginal smears**

A scoring system from Gram-stained vaginal smears is provided. The score ranges from 0 to 10, with lower scores indicating normal levels of lactobacilli and higher scores indicating abnormal conditions. The score is calculated by adding the counts of lactobacillus, Gardnerella, and Bacteriodes spp. morphotypes.

<table>
<thead>
<tr>
<th>Total Score</th>
<th>Lactobacillus morphotypes</th>
<th>Gardnerella and Bacteriodes spp. morphotypes</th>
<th>Curved gram variable rods</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>4 (30/oif)</td>
<td>0(0/oif)</td>
<td>0</td>
</tr>
<tr>
<td>1</td>
<td>3 (5-30/oif)</td>
<td>1 (1/oif)</td>
<td>1 or 2</td>
</tr>
<tr>
<td>2</td>
<td>2 (1-4/oif)</td>
<td>2 (1-4/oif)</td>
<td>3 or 4</td>
</tr>
<tr>
<td>3</td>
<td>1 (1/oif)</td>
<td>3 (5-30/oif)</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>0 (0/oif)</td>
<td>4 (30/oif)</td>
<td></td>
</tr>
</tbody>
</table>

*Morphotypes are scored as the average number seen per oil immersion field (oif). Note that less weight is given to curved Gram-variable rods. Total score = lactobacilli + G. vaginalis and Bacteriodes spp. + curved rods.

0 = no morphotypes present
1 = 1 morphotype present
2 = 1 to 4 morphotypes present
3 = 5 to 30 morphotypes present
4 = 30 or more morphotypes present.

**Interpretation of Nugent score**

0-3 normal, never treat
4-6 intermediate, decide on symptoms for treatment
7-10 Treat
Fig A1e: Gram stained vaginal smear showing a normal flora of lactobacilli (x 1000)

Fig A1f: Gram stained vaginal smear with typical “clue cell” (x 1000)

Fig A1g: Gram stained vaginal smear showing large Gram-negative rods (Mobilincus mulieris) (x 1000)
Use of gram stain for diagnosis of cervical infection

1. The Gram stain method in female does not provide conclusive evidence of the presence of Gonococcal infection. Presence of gram negative diplococci indicates infection but their absence does not rule out infection.

2. The costs associated with the method, including the cost of maintaining microscopes, outweigh the benefits in terms of improved quality of care.

Rapid Plasma Reagin (RPR) test for Syphilis

The current nontreponemal tests for syphilis are Venereal Disease Research Laboratory (VDRL) and rapid plasma reagin (RPR) test. RPR test is most suitable for the primary health care set-up.

**Procedure of RPR test**

- Inform about the infection and the procedure for diagnosis
- Seek consent
- Use a sterile needle and syringe. Draw 5 ml of blood from a vein. Put in a plain test tube
- Let the test tube stand for 20 minutes to allow serum to separate (Or centrifuge 3-5 minutes at 2000-3000 rpm). In the separated sample, serum will be on top.
Use sampling pipette to transfer the serum. Take care not to include any red blood cells from the lower part of the separated sample.

Hold the pipette vertically over a test card circle. Squeeze teat to allow one drop (50 µl) of serum to fall onto a circle. Spread the drop to fill the circle using a toothpick or other clean spreader.

Important: Several samples may be done on one test card. Be careful not to contaminate the remaining test circles. Use new tip and spreader for each sample. Carefully label each sample with a Client name or number.

Attach dispensing needle to a syringe. Shake antigen. Draw up enough antigen for the number of tests done (one drop per test).

Holding the syringe vertically, allow exactly one drop of antigen to fall onto each test sample. Do not stir.

Rotate the test card smoothly on the palm of the hand for 8 minutes (or rotate on a mechanical rotator.)

Interpreting results

After 8 minutes rotation, inspect the card in good light. Turn or tilt the card to see whether there is clumping (reactive result). Test cards include negative and positive control circles for comparison.

Example test card

1. Non-reactive (no clumping or only slight roughness): Negative for syphilis
2. Reactive (highly visible clumping): Positive for syphilis
3. Weakly reactive (minimal clumping): Positive for syphilis

Note: Make sure antigen was refrigerated (not frozen) and has not expired.

If RPR positive

- Enquire if the woman and her partner have received proper treatment.
- If not, treat woman and partner for syphilis with benzathine penicillin.
- Treat newborn with benzathine penicillin.
- Follow-up newborn in 2 weeks.
- Counsel on safer sex.
Correlation and confirmation of test results

- Syphilis tests detect antibodies, which are evidence of current or past infection. Syphilis tests are not needed to diagnose Clients with genital ulcers (who should be managed using Flowchart).

- Non-treponemal tests (such as RPR and VDRL) are the preferred tests for screening. These tests detect almost all cases of early syphilis, but false positives are possible. RPR can be performed without a microscope.

Treponemal tests, such as Treponema pallidum haemagglutination test (TPHA), fluorescent Treponema antibody absorption test (FTA-Abs), microhaemagglutination assay for antibodies to *Treponema pallidum* (MHA-TP), if available, can be used to confirm non-treponemal test results.

Quantitative RPR titres can help evaluate the response to treatment.

The following table can be used to interpret syphilis test results.

**Box A1.6: Interpreting serological test results**

<table>
<thead>
<tr>
<th></th>
<th>RPR</th>
<th>RPR titre</th>
<th>TPHA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active infection</td>
<td></td>
<td>1:8</td>
<td></td>
</tr>
<tr>
<td>Latent syphilis</td>
<td></td>
<td>Often 1:4</td>
<td></td>
</tr>
<tr>
<td>False positive</td>
<td></td>
<td>Usually 1:4</td>
<td>-</td>
</tr>
<tr>
<td>Successful treatment</td>
<td>or -</td>
<td>2 titres decrease (e.g. from 1:16 to 1:4)</td>
<td></td>
</tr>
</tbody>
</table>
CONDOM AND ITS PROPER USAGE TECHNIQUE

Condom is one of the barrier methods of contraception. They are made by using either latex or polyurethane, which cannot be penetrated by sperm, STIs or HIV, so it provides dual protection, helps in avoiding unwanted pregnancies and gives protection against STIs. Therefore promotion of the use of condoms and ready accessibility of condoms is important for the control of STIs and HIV. Management of STIs includes counseling on preventive measures and use of condoms. All health facilities providing STI services must always have in stock the essential drugs and condoms. The necessity of using condoms must be explained to the Clients along with the advice on the treatment schedule and important for compliance of the full course of medicines prescribed.

General Instructions for Condom use

Remember

- The condom does not include spermicide. If you want additional protection, you must add your own spermicide.
- Because it is made from polyurethane, you can use oil-based lubricants with the condom.
- Use a new condom each time you have sex.
- Use a condom only once.
- For best results, store condoms in a cool, dry place.
- Do not use a condom that may be old or damaged.

Do not use a condom if

- The package is broken.
- The condom is brittle or dried out.
- The color is uneven or has changed.
- The condom is unusually sticky.

Male Condom

Most male condoms are made of latex, while some are made of polyurethane. Male condoms are of two types: Non lubricated and lubricated.
### Box A2. How to use a male condom

#### Step 1: Open Package
- Use a new condom each time you have sex
- Check that it has not expired and that the packaging has no holes by pressing the pack between your fingers
- Push condom to one side of package to allow room to tear open other side
- Remove condom carefully
- DO NOT use finger nails, teeth or sharp objects to open package or remove condom

#### Step 2: Put it on
- Squeeze closed top end of condom to make sure no air is inside (can make it break)
- Place condom over top of erect penis
- With other hand, unroll condom gently down the full length of your penis (one hand still squeezing top end)

#### Step 3: During sex
- Make sure condom stays in place
- If it comes off, withdraw your penis and put on a new condom before intercourse continues
- Once sperm has been released into condom (ejaculation), withdraw the erect penis and HOLD the condom in place on penis

#### Step 4: Dispose of condom
- Remove condom ONLY when penis is fully withdrawn
- Keep both penis and condom clear from contact with your partners body
- Knot the end of the used condom
- Place in tissue or bag before throwing it in dustbin
- DO NOT flush condoms down the toilet. It will block the system
Female Condom

Female condoms are made of polyurethane. One advantage of it over the male condom is that its size and shape enable it to cover the wider surface area including some of the external genitalia, thus it may offer additional protection against infections that can be transmitted by contact with skin normally not covered by a male condom. However, the female condom is expensive. It is freely available in open market but not yet included in the National family Welfare program.

**Box A2.2 How to use a female condom**

<table>
<thead>
<tr>
<th>Before Intercourse</th>
<th>Step</th>
<th>Open Package</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Remove the female condom from the package, and rub it between two fingers to be sure the lubricant is evenly spread inside the sheath. If you need more lubrication, squeeze two drops of the extra lubricant included in the package into the condom sheath.</td>
<td><strong>Step 1</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Step 2</th>
<th>Put it in</th>
</tr>
</thead>
<tbody>
<tr>
<td>• The closed end of the female condom will go inside your vagina. Squeeze the inner ring between your thumb and middle finger.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Step</th>
<th>Assure right position</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Insert the ring into your vagina. Using your index finger, push the sheath all the way into your vagina as far as it will go. It is in the right place when you cannot feel it. Do not worry, it can’t go too far. <strong>No e The l rica ion on he emale con om ill ma ei sli er so a e o r ime o inser i</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>During sex</th>
<th>Step</th>
</tr>
</thead>
<tbody>
<tr>
<td>• The ring at the open end of the female condom should stay outside your vagina and rest against your labia (the outer lip of the vagina). Be sure the condom is not twisted.</td>
<td></td>
</tr>
</tbody>
</table>

| • Once you begin to engage in intercourse, you may have to guide the penis into the female condom. If you do not, be aware that the penis could enter the vagina outside of the condom’s sheath. If this happens, you will not be protected. |  |

<table>
<thead>
<tr>
<th>After Intercourse</th>
<th>Step</th>
<th>Dispose of condom</th>
</tr>
</thead>
<tbody>
<tr>
<td>• You can safely remove the female condom at any time after intercourse. If you are lying down, remove the condom before you stand to avoid spillage.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| • Throw the female condom away. Do not reuse it. |  |

*During intercourse remember to remove and insert a new female condom if con om ri s or ears ring inser ion or ears ring inser ion or se he o er ring is she insi e he enis en ers o si e he o ch he con om nches insi e he vagina or o have se again*
STI Clinic Setup

A. Internal structure

The internal structure of the clinic should provide physical privacy, auditory privacy and confidentiality for Client interviews and information in the following areas:

- Waiting and registration area;
- Consultation and examination room, with door;
- Laboratory area (if feasible); and
- Counseling room, with door.

All areas should have adequate lighting and ventilation.

B. Staffing

Staffing should be adequate for the following clinic functions to be carried out in a timely manner, without excessive waiting times:

- Clinic administration, Client registration, record-keeping and reporting;
- Sexual and reproductive health history-taking, clinical examination and Client management, including counseling and education;
- Laboratory-based diagnostic testing (where applicable);
- Maintenance of clinical standards for STI management; and
- Procurement and maintenance of clinic supplies.

All clinic staff positions should be filled at all time with appropriately trained personnel. New staff should be trained in elements of STI Case management.

C. Equipment and Drugs

Equipment should be maintained in good working order.

Equipment should be maintained by:

- Wiping / dusting daily with clean cloth
- Cover with protective covering

Condoms, drugs and other supplies should always be in stock in the clinic. Availability of blister pack of drugs colour coded for different syndromes may be considered.

D. Coordination between clinic staff and outreach services (wherever applicable)

Close collaboration and communication between the clinic and outreach staff will help in identifying and addressing problems and removing misunderstandings between the clinic and community in a timely manner.

- Regularly scheduled meetings should be held with clinic staff, project outreach staff and peer educators to discuss
- Clinic activities;
- Community needs and concerns;
- Ways of promoting the clinic;
- Follow-up of cases in the community; and
- The ongoing process of coordination.

- Outreach worker should be encouraged to report back to clinic staff on issues such as community perception of the clinic, treatment compliance, side effects of medications, etc.
- A community monitoring system should be in place.
- Clinic staff should participate in outreach visits on a regular basis.

E. **Client friendly environment**

Five components of a clinic environment that are acceptable to Clients and promote trust within the community are:

- Respectful attitude of staff;
- Convenient location and clinic opening hours;
- Confidentiality;
- Anonymity; and
- Right of refusal of services.

Confidentiality should be ensured at all times. This must be continually reinforced with the staff.

- Clinics should have a confidentiality policy that is enforced and communicated to the Clients and community.
- Clients should be informed about how their medical information is handled, and when and how such data may be used for evaluation purposes.
- All staff should receive training in the confidentiality policies of the clinic.
- All staff should sign a confidentiality agreement.

Anonymity can be preserved by allowing Clients to provide identifying information, such as a “working name”, age, date of birth, etc., instead of their official birth name. It is not necessary to ask for identification papers. A registration number can be assigned to each Client as his/her identifying information. S/he should be instructed to keep this to ensure continuity of service in the clinic.

All Clients have a right to refuse services, even when the clinic staff may think they are in the Client’s best interest. Clients should not be forced into attending the clinic or receiving treatment. If the Client still refuses treatment after exploring and discussing the reasons for resisting examination or treatment, the clinician must respect the Client’s choice. It is possible that the Client will allow examination on a subsequent visit after a trust in the clinic’s staff is established.
## LIST OF DRUGS

### Drugs to be stocked at STI Clinics

All clinics must maintain adequate stock of drugs required for treatment of STIs as per the standard protocol. Following is the inventory of essential STI treatment drugs. They should be stored in a secure location and used before their expiry date.

1. **Inj. Benzathene Penicillin** 24 lakhs unit vial
2. **Inj. Ceftriaxone** (250 mg & 1 gm)
3. **Tab. Azithromycin** (1g)
4. **Tab. Cefixime** (400mg)
5. **Tab. Fluconazole** (150 mg)
6. **Tab. Secnidazole** (500 mg)
7. **Tab Metronidazole** (400 mg)
8. **Tab. Erythromycin** (500 mg) base/stearate
9. **Cap. Doxycycline** (100 mg)
10. **Cap. Acyclovir** (400 mg)
11. **Clotrimazole Vaginal pessary** (500 mg)
12. **Podophyllin tincture** 20%
13. **Permethrin cream** (5%) and (1%)
DISINFECTION AND UNIVERSAL PRECAUTIONS

The terms “standard precautions” and additional (transmission-based) precautions have replaced previous terms such as universal blood and body fluid precautions, universal precautions and barrier nursing.

Standard precautions require that health care workers assume that the blood and body substances of all patients are potential sources of infection, regardless of the diagnosis or presumed infectious status.

Additional (transmission-based) precautions are needed for diseases transmitted by air, droplets and contact.

A number of RTIs can be spread from patient to health care provider or to other patients if basic precautions are not followed. Hepatitis B and C viruses and HIV are incurable infections that are easily transmitted by reuse of contaminated sharps. Because RTIs are often asymptomatic, it is not possible to know which patients have an infection. For this reason, standard precautions should be followed by all the health care workers.

Standard precautions

Standard precautions include the following:

1. Hand washing and antisepsis (hand hygiene)
2. Use of personal protective equipment when handling blood, body substances, excretions and secretions
3. Appropriate handling of patient equipment and soiled linen
4. Prevention of needle-stick/sharp injuries
5. Management of health care waste

Hand washing

Hand washing breaks the chain of infection transmission and reduces person-to-person transmission. It is the most important way to kill germs on the skin. You need to wash your hands even more thoroughly and for a longer time in the following situations:

- before and after helping someone give birth;
- before and after touching a wound or broken skin;
- before and after giving an injection, or cutting or piercing a body part;
- after touching blood, urine, stool, mucus, or fluid from the vagina; and
- after removing gloves;
- between contact with different patients
The hands must be washed for a minimum of 10-15 seconds, count to 30 as you scrub your hands all over with the soapy lather. Use soap or other disinfectant to remove dirt and germs. Use a brush or soft stick to clean under your nails, then rinse, using running water. Do not reuse the same water. Immersion of hands in bowls of antiseptics is not recommended. Common towels must not be used as they facilitate transmission of infection. If there is no clean dry towel, it is best to air-dry hands.

**Fig A a Hand washing Procedures**

![Hand washing procedures diagram]


- Hand washing is the simplest and most cost-effective way of preventing the transmission of infection
- The hands must be washed for a minimum of 10-15 seconds with soap or other disinfectant
- Common towels must not be used as they facilitate transmission of infection
2. Use of personal protective equipment when handling blood, body substances, excretions and secretions

Using personal protective equipment offers protection by helping to prevent microorganisms from-

- Contamination of hands, eyes, clothing, hair
- Being transmitted to other patients and staff

Personal protective equipment includes:

- Gloves
- Masks
- Aprons
- Gowns
- caps/hair covers

**Gloves**

- Use of gloves (clean, non-sterile) or a piece of plastic for handling dirty bandages, cloths, blood, vomit or stool.
- Disposable gloves should not be reused
- Gloves must be changed not only between contacts with different patients but between tasks/procedures on the same patient to prevent cross-contamination between different body sites.

Personal protective equipment must be used effectively, correctly and at all times where there is contact with patient’s blood, body fluids, excretions and secretions may occur

**Appropriate handling of patient equipment and soiled linen**

Ensure that all reusable equipment is cleaned and reprocessed appropriately before being used on another patient.

Keep bedding and clothing clean. This helps in keeping sick people comfortable and helps in preventing skin problems. Handle clothing and/or sheets carefully, which are stained with blood, urine, stool or other body fluids. Separate from other laundry for washing. Dry laundry thoroughly in the sun if possible or iron after drying.

**Prevention of needlestick sharp injuries**

All the used disposable syringes and needles, scalpel blades and other sharp items should be placed in a puncture resistant container having a proper lid. These containers must be located close to the area. Never recap or bend needles.
Guidelines for Setting Up Blood Storage Centres

5. Management of health care waste

Daily collection of waste must be encouraged and uncollected, long stored waste or waste within the premises must be avoided. The bio-medical waste should be segregated into containers/bags at the point of its generation into colour coded containers/bags. Table 12a gives the colour, coding, type of containers used and multiple treatment options for disposal of the bio-medical waste.

Table A5a: Management of health care waste

<table>
<thead>
<tr>
<th>Colour coding</th>
<th>Type of container</th>
<th>Waste category</th>
<th>Treatment and disposal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yellow/Red</td>
<td>Plastic bag</td>
<td>Human anatomical waste (Human tissues, organs, body parts)</td>
<td>Incineration/deep burial*</td>
</tr>
<tr>
<td>Blue/ white</td>
<td>Puncture proof container</td>
<td>Waste sharps (Needles, syringes, scalpels, blades, glass etc. that may cause puncture and cuts)</td>
<td>Chemical treatment# /autoclaving /shredding##</td>
</tr>
<tr>
<td>translucent</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>Plastic bag</td>
<td>Discarded medicines (Wastes comprising of outdated, contaminated and discarded medicines)</td>
<td>Incineration , destruction and drug disposal in secured landfills</td>
</tr>
<tr>
<td>Yellow/Red</td>
<td>Disinfected container/plastic bag</td>
<td>Solid waste (Items contaminated with blood and body fluids including cotton, dressings, linen, beddings or other material contaminated with blood)</td>
<td>Incineration/autoclaving</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>Liquid waste ( waste generated from laboratory and washing, cleaning, housekeeping and disinfecting activities)</td>
<td>Disinfection with chemical treatment# and discharge into drains</td>
</tr>
</tbody>
</table>

* Deep burial should be done in a secure area. Burial should be 2 to 3 meters deep and at least 1.5 meters above the groundwater table.

# Chemical treatment using at least 1% hypochlorite solution or any other equipment chemical reagent. It must be ensured that chemical treatment ensures disinfection.

## Shredding must be such so as to prevent unauthorized use of sharp waste.
Standard precautions require that health care workers assume that the blood and body substances of all patients are potential sources of infection, regardless of the diagnosis or presumed infectious status. Additional (transmission-based) precautions are needed for diseases transmitted by air, droplets and contact. A number of RTIs can be spread from patient to health care provider or to other patients if basic precautions are not followed. Hepatitis B and C viruses and HIV are incurable infections that are easily transmitted by reuse of contaminated sharps. Because RTIs are often asymptomatic, it is not possible to know which patients have an infection. For this reason, standard precautions should be followed by all the health care workers.

Disinfection of instruments

Disinfect or sterilize equipment and instruments. Instruments must first be washed and then disinfected if they are to be used to:

- cut or pierce skin;
- give an injection;
- cut the cord during childbirth;
- examine the vagina, especially during or after childbirth, a miscarriage, or an induced abortion;
- perform any transcervical procedure.

High level disinfection three steps

Cleaning instruments and equipment to get rid of nearly all the germs is called high-level disinfection. The following procedures could be followed to achieve it:

1. **Soaking**: Soak instruments for 10 minutes in 0.5% solution of bleach (chlorine). Soaking instruments in bleach solution will help protect you from infection when cleaning them. If you do not have bleach, soak your instruments in water.
2. **Washing**: Wash all instruments with soapy water and a brush until each one looks very clean, and rinse them with clean water. Be careful not to cut yourself on sharp edges or points. Wear gloves when washing instruments; if possible, use heavy gloves.
3. **Disinfecting**: Steam or boil the instruments for 20 minutes.
   - To steam them, you need a pot with a lid. The water does not need to cover the instruments, but use enough water to keep steam coming out of the sides of the lid for 20 minutes. Do not overload with instruments. No instruments should protrude above the rim of the pot.
   - To boil them, you do not need to fill the whole pot with water. But you should make sure the water covers all the instruments in the pot for the entire time. Put a lid on the pot.
   - For both steaming and boiling, start timing the 20 minutes after the water
Guidelines for Setting Up Blood Storage Centres

National AIDS Control Organisation

with the instruments is fully boiling. Do not add any new instrument to the pot once you begin to count.

Table shows how to make a disinfection solution of 0.5%, 1% and 2% available chlorine

Table A b Hypochlorite solution of 0.5%, 1% and 2% available chlorine

<table>
<thead>
<tr>
<th>Product</th>
<th>Chlorine available</th>
<th>How to dilute to 0.5%</th>
<th>How to dilute to 1%</th>
<th>How to dilute to 2%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium hypochlorite - liquid bleach</td>
<td>3.5%</td>
<td>1 part bleach to 6 parts water</td>
<td>1 part bleach to 7.5 parts water</td>
<td>1 part bleach to 17 parts water</td>
</tr>
<tr>
<td>Sodium hypochlorite - liquid</td>
<td>5%</td>
<td>1 part bleach to 9 parts water</td>
<td>1 part bleach to 4 parts water</td>
<td>1 part bleach to 1.5 parts water</td>
</tr>
<tr>
<td>NaDCC (sodium dichloro - isocyanurate) - powder</td>
<td>60%</td>
<td>8.5 grams to 1 litre water</td>
<td>17 grams to 1 litre water</td>
<td>34 grams to 1 litre water</td>
</tr>
<tr>
<td>NaDCC (1.5g / tablet) - tablets</td>
<td>60%</td>
<td>6 tablets to 1 litre water</td>
<td>11 tablets to 1 litre water</td>
<td>23 tablets to 1 litre water</td>
</tr>
<tr>
<td>Chloramine - powder</td>
<td>25%</td>
<td>20 grams to 1 litre water</td>
<td>40 grams to 1 litre water</td>
<td>80 grams to 1 litre water</td>
</tr>
</tbody>
</table>

Note: Bleach solution becomes unstable rapidly, hence it needs to be freshly prepared daily or changed on becoming dirty/ turbid. Chlorine bleach can be corrosive. Protect metal instruments by thoroughly rinsing them in water after soaking for 10 minutes.

Cleaning of the Heath Centers

Patient care areas must be cleaned by wet mopping. Only dry sweeping is not recommended. Any areas visibly contaminated with blood or body fluids should be cleaned immediately with detergent and water.
Table A5c Common disinfectants used for environmental cleaning in health centers

<table>
<thead>
<tr>
<th>Disinfectants</th>
<th>Recommended use</th>
<th>Precautions</th>
</tr>
</thead>
</table>
| Sodium hypochlorite 1%         | Disinfections of material contaminated with blood and body fluids                | • Should be used in well-ventilated areas  
• Protective clothing required while handling and using undiluted solutions  
• Do not mix with strong acids to avoid release of chlorine gas  
• Corrosive to metals |
| In-use dilution, 5% solution to diluted 1:5 in clean water |                                                                                  |                                                                                                |
| Bleaching powder 7g/litre with 70% available chlorine (Table shows dilutions for bleach) | Toilets / bathrooms – If liquid bleach is not available, this may be used | Same as above                                                                                   |
| Alcohol (70%) Isopropyl, ethyl alcohol, methylated spirit | Smooth metal surfaces, tabletops and other surfaces on which bleach cannot be used | • Flammable, toxic, to be used in well-ventilated area, avoid inhalation  
• Kept away from heat source, electrical equipment, flames, hot surfaces  
• Allow it to dry completely, particularly when using diathermy as it can cause diathermy burns |

**Note:** A neutral detergent and warm water solution should be used for all routine and general cleaning. When a disinfectant is required for surface cleaning, e.g., after spillage or contamination with blood or body fluids, the manufacturer’s recommendation for use and occupational health and safety instruction should be followed.
MONTHLY REPORT FORMAT
(National AIDS Control Programme)

Reporting Month: ____________________
Name of Centre: ____________________
Name of Block: ____________________
Name of District: ____________________
Name & Phone No. of Officer In Charge: ____________________

<table>
<thead>
<tr>
<th>Type of Patients</th>
<th>Age Group &amp; Sex</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt;19</td>
<td>20-30</td>
</tr>
<tr>
<td></td>
<td>Male</td>
<td>Female</td>
</tr>
<tr>
<td>New</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Old</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diagnosis</td>
<td>Age Group &amp; Sex</td>
<td>Total</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>-----------------</td>
<td>-------</td>
</tr>
<tr>
<td></td>
<td>&lt;19 M F</td>
<td>20-30 M F</td>
</tr>
<tr>
<td>1. Vaginal discharge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Vaginitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• BV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Candidiasis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Trichomoniasis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Cervicitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Gonococcal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Chlamydia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Lower abdominal pain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Genital Ulcer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Syphilis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Chancroid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• LGV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Herpes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Urethral Discharge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Gonococcal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Chlamydia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Inguinal bubo</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Other STIs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total no of cases</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# Laboratory Clinical Diagnosis

<table>
<thead>
<tr>
<th>Type of Diseases</th>
<th>Age Group</th>
<th>Sex</th>
<th>Laboratory Tests</th>
<th>Nos. Tested</th>
<th>Nos. Found Positive</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Syphilis</td>
<td></td>
<td></td>
<td>Dark Field Microscopy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Serology - VDRL/RPR</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Gonorrhoea</td>
<td></td>
<td></td>
<td>Direct Smear (Grams's Stain)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Culture</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Chlamydia</td>
<td></td>
<td></td>
<td>ELISA Antibody</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Chancroid</td>
<td></td>
<td></td>
<td>Gram's / Glemsa Staining</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Trichomonias</td>
<td></td>
<td></td>
<td>Direct wet mount</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Candiadiasis</td>
<td></td>
<td></td>
<td>KOH wet mount</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Bacterial Vaginosis</td>
<td></td>
<td></td>
<td>Wet mount preparation for clue cells</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Others (specify)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Details of Condom Distribution, Partner Treatment and Counseling Services

<table>
<thead>
<tr>
<th>Details</th>
<th>Male</th>
<th>Female</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Number of condoms distributed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Number of female condoms distributed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Number of partners managed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Number of patients referred to ICTC</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Status of Availability of Medicines and Consumables (Stock Details)

<table>
<thead>
<tr>
<th>Details</th>
<th>Whether available in adequate quantity for the next three months</th>
<th>If no, List the ones not available in adequate quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yes / No</td>
<td></td>
</tr>
<tr>
<td>1. Consumables</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Medicines for Treating STD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Male Condoms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Female Condoms</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Details of Staff at the STD Clinic/Gynaecology OPD

<table>
<thead>
<tr>
<th>Details of Staff at STD Clinic/Gynaecology OPD</th>
<th>Sex</th>
<th>Whether specialised in Skin &amp; VD</th>
<th>Whether Received Training on STD Case Management / Lab test</th>
<th>Month &amp; Year of Last Training</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Medical Officer</td>
<td>1. Male</td>
<td>1. Yes</td>
<td>1. Yes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Female</td>
<td>2. No</td>
<td>2. No</td>
<td></td>
</tr>
<tr>
<td>2. Medical Officer</td>
<td>1. Male</td>
<td>1. Yes</td>
<td>1. Yes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Female</td>
<td>2. No</td>
<td>2. No</td>
<td></td>
</tr>
<tr>
<td>3. Medical Officer</td>
<td>1. Male</td>
<td>1. Yes</td>
<td>1. Yes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Female</td>
<td>2. No</td>
<td>2. No</td>
<td></td>
</tr>
<tr>
<td>4. Lab Technician</td>
<td>1. Male</td>
<td>1. Yes</td>
<td>1. Yes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Female</td>
<td>2. No</td>
<td>2. No</td>
<td></td>
</tr>
<tr>
<td>5. Lab Attendant</td>
<td>1. Male</td>
<td>1. Yes</td>
<td>1. Yes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Female</td>
<td>2. No</td>
<td>2. No</td>
<td></td>
</tr>
<tr>
<td>6. Counsellor (inhouse/attached to ICTC)</td>
<td>1. Male</td>
<td>1. Yes</td>
<td>1. Yes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Female</td>
<td>2. No</td>
<td>2. No</td>
<td></td>
</tr>
</tbody>
</table>
REFERENCES AND SOURCE

We gratefully acknowledge the use of material that has been adapted from the following sources:

<table>
<thead>
<tr>
<th>Source</th>
<th>Publication</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>World Health Organisation</td>
<td>Guidelines for the Management of Sexually Transmitted Infections</td>
<td>2003</td>
</tr>
<tr>
<td>World Health Organisation</td>
<td>Sexually Transmitted and Other Reproductive Tract Infections A Guide to essential Practice</td>
<td>2005</td>
</tr>
<tr>
<td>World Health Organisation</td>
<td>Draft Global Strategy for the Prevention and Control of Sexually Transmitted infections</td>
<td>2005</td>
</tr>
<tr>
<td>World Health Organisation</td>
<td>Practical guidelines for Infection Control in Health Care Facilities, SEARO, New Delhi</td>
<td>1999</td>
</tr>
<tr>
<td>Centre for Disease Control</td>
<td>Guidelines for Treatment of STDs</td>
<td>2002</td>
</tr>
<tr>
<td>Clinical Effectiveness Group</td>
<td>UK National Guidelines on STIs</td>
<td>2002</td>
</tr>
<tr>
<td>Population Services International</td>
<td>Flowcharts for STIs in Males</td>
<td>2004</td>
</tr>
<tr>
<td>Family Health International</td>
<td>Handbook for design and management of programs</td>
<td>2005</td>
</tr>
<tr>
<td>Indian Council of Medical Research</td>
<td>Guidelines for Management of Reproductive Tract Infections: For Medical Officers at PHCs</td>
<td>1996</td>
</tr>
<tr>
<td>National AIDS Control Organisation</td>
<td>Sexually Transmitted Infections-Treatment Guidelines</td>
<td>Draft</td>
</tr>
<tr>
<td>National AIDS Control Organisation</td>
<td>Flowcharts on the Syndromic Management of Sexually Transmitted Infections</td>
<td>2004</td>
</tr>
<tr>
<td>United Nations Population Fund</td>
<td>Reference Material on Case Management of RTIs/STIs in PHC Settings for Medical Officers</td>
<td>2004</td>
</tr>
<tr>
<td>Pathfinder International</td>
<td>Comprehensive Reproductive Health and Family Planning Training Curriculum (Module 12)</td>
<td>2000</td>
</tr>
<tr>
<td>Engender Health</td>
<td>Sexually Transmitted Infections Online minicourse</td>
<td>2006</td>
</tr>
</tbody>
</table>

We gratefully acknowledge the use of pictures from the following sources:

1. Dept of Skin & Venereal diseases, Lokmanya Tilak Medical College and Sion Hospital, Sion, Mumbai
2. Dept of Skin & Venereal diseases, Seth G S Medical College and KEM Hospital, Parel, Mumbai
3. Bharatiya Vidya Bhavan s Swami Prakashananda Ayurveda Research Centre (SPARC), Juhu, Mumbai
Coordinating Unit at National Institute for Research In Reproductive Health, Mumbai

Dr. Chander Puri, Director
Dr. Sanjay Chauhan, Deputy Director
Dr. Beena Joshi, Research Officer
Dr. Ragini Kulkarni, Research Officer
Dr. Kamal Hazari, Deputy Director
Dr. Rajashree Manjrekar, Project Research Officer

CORE GROUP MEMBERS

Department of Maternal Health, Ministry of Health and Family Welfare, Government of India

Dr. V.K. Manchanda, Deputy Director General (retired)
Dr. (Mrs) I. P. Kaur, Deputy Commissioner
Dr. Himanshu Bhushan, Assistant Commissioner
Dr. (Mrs) Manisha Malhotra, Assistant Commissioner

National AIDS Control Organisation

Dr. Jotna Sokhey, Additional Project Director
Dr. Ajay Khera, Joint Director (Surveillance)
Dr. Vinod Khurana, Consultant & Programme Officer

World Health Organisation, India Office

Dr. Arvind Mathur, Coordinator, Family & Community Health

United Nations Population Fund

Dr. Dinesh Agarwal, Technical Advisor (Reproductive Health)
### List of Contributors

<table>
<thead>
<tr>
<th>Name</th>
<th>Position and Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prof (Ms) Sajida Ahmed</td>
<td>Prof &amp; Head, Department of Community Medicine, Medical College, Guwahati, Assam</td>
</tr>
<tr>
<td>Dr (Ms) Rekha Daver</td>
<td>Prof. &amp; Head, Dept. of OBG N, Grant Medical College &amp; J.J. Hospital, Byculla, Mumbai</td>
</tr>
<tr>
<td>Dr. (Mrs) Alka Gogate</td>
<td>Consultant Microbiologist (UNAIDS) 12, Sahyog Hsg Society, Mahim, Mumbai</td>
</tr>
<tr>
<td>Dr. R.R. Gangakhedkar</td>
<td>Deputy Director, National AIDS Research Institute, ICMR, MIDC, Bhosari, Pune</td>
</tr>
<tr>
<td>Dr. S. D. Gupta</td>
<td>Director, International Institute of Health Management &amp; Research, Sanganer, Jaipur</td>
</tr>
<tr>
<td>Dr. Jayashree Joshi</td>
<td>Deputy Director, Bharatiya Vidy Bhavan s SPARC, Vithalnagar, Juhu, Mumbai</td>
</tr>
<tr>
<td>Dr. Surinder Jaiswal</td>
<td>Professor, Tata Institute of Social Sciences, Deonar, Mumbai</td>
</tr>
<tr>
<td>Dr. Hema Jerajani</td>
<td>Professor and Head, Dept. of Skin and VD, LTMC &amp; LTM General Hospital, Sion, Mumbai</td>
</tr>
<tr>
<td>Dr. H. K. Kar</td>
<td>Professor and Head, Department of Dermatology and Venerology, R.M.L. Hospital, New Delhi</td>
</tr>
<tr>
<td>Dr. Usha Krishna</td>
<td>Consulting Gynecologist, Clinic for Women, Girgaon, Mumbai</td>
</tr>
<tr>
<td>Dr. Sunil Khaparde</td>
<td>Director, Institute of Family Welfare Research &amp; Training, Khetwadi, Mumbai</td>
</tr>
<tr>
<td>Dr. Uday Khopkar</td>
<td>Professor and Head, Department of Skin and VD, Seth G.S. Medical College, Parel, Mumbai</td>
</tr>
<tr>
<td>Dr. Renuka Kulkarni</td>
<td>Professor, Dept of Clinical PharmacologyTNMC &amp; B L Nair hospital, Mumbai</td>
</tr>
<tr>
<td>Dr. (Mrs) Meenaksi Mathur</td>
<td>Prof and Head, Department of Microbiology, LTMC &amp; LTM General Hospital, Sion, Mumbai</td>
</tr>
<tr>
<td>Dr. Jayanti Mania</td>
<td>Assistant Director, National Institute for Research in Reproductive Health, (ICMR), Parel, Mumbai</td>
</tr>
<tr>
<td>Dr. B. N. Mali</td>
<td>SRO, National Institute for Research in Reproductive Health, (ICMR), Parel, Mumbai</td>
</tr>
<tr>
<td>Dr. Deoki Nandan</td>
<td>Principal &amp; Dean of Hospital, S. N. Medical College, Agra</td>
</tr>
<tr>
<td>Surg. Cdr (Dr.) Shankar Narayan</td>
<td>Specialist in Neonatology, Dept. of PaediatricsNHS Ashvini, Colaba, Mumbai</td>
</tr>
<tr>
<td>Dr. P. Padmanaban</td>
<td>Director, RCH Project, Govt.of Tamil Nadu, DMS Bldg, Anna Salai, Chennai</td>
</tr>
<tr>
<td>Dr. Deepak Raut</td>
<td>Prof. and Head, Dept. of Epidemiology, All India Institute of Hygiene &amp; Public Health, Kolkata</td>
</tr>
<tr>
<td>Dr. Foujdar Ram</td>
<td>Professor, International Institute for Population Sciences, Deonar, Mumbai</td>
</tr>
<tr>
<td>Dr. Jayanti Shastri</td>
<td>Professor, Dept of Microbiology, TNMC &amp; B L Nair Hospital, Mumbai Central, Mumbai</td>
</tr>
<tr>
<td>Dr. Sudha Salhan</td>
<td>Prof and Head, Dept. of OBG NV.M. Medical College, Safdarjung Hospital, Delhi</td>
</tr>
<tr>
<td>Dr. Usha Sariya</td>
<td>Consultant Gynaecologist and Cytopathologist, Albess Cama Hospital, Mumbai</td>
</tr>
<tr>
<td>Dr. N. Usman</td>
<td>Professor of Dermatology &amp; STDInstitute of Venerology, Chennai</td>
</tr>
<tr>
<td>Dr. Kaushal Verma</td>
<td>Dept. of Skin and Venereal Diseases, All India Institute of Medical Sciences, Ansari Nagar, Delhi</td>
</tr>
<tr>
<td>Dr. Teodora Elvira Wi</td>
<td>Director, STI Capacity Training, Family Health International, Mumbai</td>
</tr>
<tr>
<td>Dr. Sanjay Zodpey</td>
<td>Prof &amp; Head, Dept of Preventive &amp; Social Medicine, Govt. Medical College, Nagpur</td>
</tr>
</tbody>
</table>

*Names in alphabetical order*
NATIONAL GUIDELINES ON
PREVENTION, MANAGEMENT AND CONTROL OF
REPRODUCTIVE TRACT INFECTIONS
INCLUDING
SEXUALLY TRANSMITTED INFECTIONS

Ministry of Health and Family Welfare
Government of India
August 2007